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Hepatitis is an infectious disease that affects millions of people worldwide. The
current project seeks to achieve two objectives: 1) To understand how hepatitis policies
affect hepatitis prevalence in prison, and 2) To understand how hepatitis prevalence in
prison affects the general population. Using a content analysis of correctional policies
available through each state Department of Corrections (DOC) and secondary data from
the 2010 Census, Centers for Disease Control and Prevention, and Corrections
Compendium; hepatitis prevalence and policies are analyzed. The content analysis
employed for this study revealed that some states have more comprehensive policies than
others. However, all states may benefit from modifying their policies to meet
recommendations constructed by the Federal Bureau of Prisons. Findings from
descriptive statistics also suggest changes in HIV prevalence and policies positively
affect hepatitis C prevalence. Future research should be dedicated to examining how
personal interactions in prison also affect prevalence rates.
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CHAPTER I
INTRODUCTION

Hepatitis is a largely unseen disease in the United States; many people are
affected by hepatitis but few people in the public are aware of its growing prevalence.
Referred to by some as a secret epidemic, hepatitis is a persistent viral infection that
affects millions of people around the world. Epidemics are defined here as a greater
number of cases for a particular disease than would usually occur during a particular time
frame (MedicineNet, 2015). For instance, if there were typically 100 cases of a disease in
a given year, the presence of 1,000 cases of that disease in a one year period would be
considered an epidemic. The Centers for Disease Control and Prevention ([CDC]; 2014)
estimate that 4.4 million Americans are currently living with chronic hepatitis and many
are unaware of their condition.
Of particular concern to researchers is hepatitis C, one of the five strains of
hepatitis, which affects an estimated one in three people incarcerated (CDC, 2013).
Hepatitis C is one of the most prevalent types of hepatitis, due in part to the absence of a
vaccination and the fact that some individuals engage in risky behaviors that increase the
likelihood of infection. Members of certain groups (e.g., intravenous drug users) are more
likely to be infected; these groups are disproportionately more likely to be found within
the prison system. The current research project will focus on three of the five strains of
1

hepatitis: A, B, and C. These strains of hepatitis were selected based on prevalence, as
these types are most commonly found in the United States.
Problem Statement
Despite the well-documented impact of hepatitis on the general population, little
is known about one group most likely to be affected by hepatitis: prisoners. Rates of
hepatitis are likely higher in prisons than in the general population because prisoners may
participate in higher levels of risky behavior. Risky behaviors include the use of
intravenous drugs (e.g., heroin), unprotected sex, and tattooing. To mitigate risky
behaviors, many state prisons create administrative policies to deter this behavior and
prevent transmission of the disease. These policies can directly affect the health decisions
and practices that inmates engage in. Despite what we know about risky behavior in the
prison system, little research has focused on the prevalence of hepatitis in the prison
population or assessed the effect of policies on rates of hepatitis in prison. This research
will attempt to address two main questions: 1) How do current hepatitis policies affect
rates of hepatitis in state prisons? 2) How does hepatitis prevalence within state prisons
affect the general population? This study is an exploratory effort to address these
questions.
By relying on the Ecological Perspective, I will examine factors that affect
hepatitis prevalence, either positively or negatively. The Ecological Perspective was
created within the field of Epidemiology. This perspective focuses on health behavior and
uses a “bottom-up” approach to examine how individual choices affect disease
prevalence. Using this perspective, inmates would be more likely to be infected with
hepatitis as a result of their life choices. Therefore, engaging in unprotected sex,
2

intravenous drug use, and utilizing unsterilized needles for tattoos would place an inmate
at a higher risk of exposure. Individual choices can increase hepatitis prevalence;
however, the effects can be mitigated by prisons’ communicable disease policies.
This study makes a number of contributions to research in the area of hepatitis.
To my knowledge, this study is the first of its kind to use the Ecological Perspective to
understand hepatitis and is also the first to assess Kaplan, Everson, and Lynch’s (2000)
perspective within the context of the incarcerated population. Additionally, no previous
research of which I am aware has utilized a content analysis to understand how state
Department of Corrections (DOC) policies compare to guidelines created by the Federal
Bureau of Prisons (BOP). Finally, this study also adds to the literature through the
exploration of factors in the general population (e.g., demographics, healthcare spending
per capita) and the prison population (e.g., healthcare spending per inmate; HIV rate in
prison) that may affect hepatitis prevalence. The findings from this study thus are
important in expanding the knowledge base around hepatitis policies and prevalence in
prison.

3

CHAPTER II
BACKGROUND

Hepatitis is an inflammation of the liver that is typically caused by a viral
infection (World Health Organization [WHO], 2014b). This infection can be categorized
into two distinct phases: acute and chronic. Acute hepatitis typically persists between two
and 24 weeks. The symptoms include fatigue, jaundice, nausea, and abdominal pain
(National Institutes of Health [NIH], 2014b). Chronic hepatitis persists much longer than
acute hepatitis. People infected with chronic hepatitis typically do not show symptoms
during the first several weeks or months of their initial infection. This type is most often
discovered when there are elevated levels of alanine aminotransferase (ALT), an enzyme
found in the liver. However, the time period in which this elevation in ALT occurs is
largely unknown. When symptoms of chronic infection appear, they are similar to acute
hepatitis, with the exception of jaundice which is a symptom of chronic infection (NIH,
2014a).
There are five main types of hepatitis: A, B, C, D, and E. A person can become
infected with one or multiple types of hepatitis, and the infections may happen
simultaneously because many of the viruses are transmitted through similar pathways.
Both hepatitis A virus (HAV) and hepatitis E virus (HEV) are transmitted through
contaminated food or water and result in an acute phase that lasts a short time. The other
types, hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV), are
4

spread through contact with infected blood. HBV can also be disseminated through
contact with infected bodily fluids like vaginal secretion or semen (Better Health
Channel, 2013).
Defining Hepatitis
The World Health Organization (2013) suggests that hepatitis commonly refers to
an inflammation of the liver that occurs as the result of infectious agents (e.g., viruses) or
noninfectious causes (e.g., alcohol consumption, excessive medication, or narcotics).
Narcotics are particularly important to study because hepatitis may be contracted through
the use of infected drug paraphernalia such as shared needles. Hepatitis can be diagnosed
through numerous tests including physical examinations, ultrasounds, blood tests, liver
biopsies, and liver function tests. These examinations are a necessary component of
preventing hepatitis infections in the prison population. During each of these
examinations, the physician is looking for any evidence of infection, specifically any
inflammation of the liver. As part of the physical examination, a physician checks
whether the patient’s eyes or skin are yellow and presses down on the patient’s abdomen
to determine whether the liver is enlarged. Yellowing skin or a swollen liver may indicate
infection. During liver biopsies, the physician removes a sample from the liver to check
for swelling. If swelling is present, this may be indicative of hepatitis. Liver function
tests are used to identify enzyme levels. High enzyme levels are indicative of infection.
Blood tests can also be used to confirm the presence of antigens and the cause of
contagion. Increased levels of antigens suggest that the body is fighting off a virus and
can indicate how long a person has been infected. Finally, using an ultrasound, a
5

physician can examine parts of an individual’s organs to determine whether there is
swelling or liver damage (Kahn, 2012).
Several prevention strategies exist to reduce the spread of hepatitis. The first
emphasizes the need to practice good hygiene. If traveling internationally, it is best to
avoid local water, seafood, raw fruits, and vegetables. These foods may contain infected
fecal matter that could lead to illness. All people, regardless of what country they are
visiting, should avoid contact with blood. A person can decrease the likelihood of coming
into contact with infected blood by not sharing drug paraphernalia or personal items such
as needles, razors, or toothbrushes (Kahn, 2012). In addition to avoiding risky behavior,
there are vaccines available to prevent HAV and HBV. It is recommended that children
are vaccinated at an early age in order to prevent risk of infection (CDC, 2014).
Although the global prevention strategies listed above are promising strategies to
reduce the transmission of hepatitis, each type is spread differently. Therefore, people
must be aware of what factors increase their risk of disease and try to avoid those
behaviors. This study focuses mainly on hepatitis A, B, and C within the prison system.
However, it is important to understand all five types of hepatitis, HIV, and Tuberculosis
because many of the viruses are contracted through similar pathways. A person may
become co-infected with multiple types of disease simultaneously (e.g., hepatitis B/D;
hepatitis B/Tuberculosis, hepatitis C/HIV). A detailed overview of each of the
aforementioned infectious diseases is mentioned below.
Hepatitis A Virus
The hepatitis A virus (HAV) is spread through the consumption of food or water
contaminated with human waste. It can also be spread through sexual contact but it
6

cannot be transmitted through casual interactions, such as being in the same room as
someone who is infected. An estimated 1.4 million cases of HAV occur each year,
primarily in developing countries that lack clean water and good sanitation. The virus is
also prevalent in areas where food production processes do not neutralize the virus.
People at the greatest risk for HAV are intravenous drug users, males who engage in
same sex practices, travelers to infected areas, and isolated communities (WHO, 2013).
The National Digestive Diseases Information Clearinghouse (NDDIC) also suggests that
daycare workers and children are an at risk population.
For those who do become infected, HAV does not progress to advanced stages,
such as chronic liver conditions, but may leave those infected feeling physically fatigued.
Typically, the virus is inactive for the initial two to four weeks before the host
experiences its effects. Symptoms vary from person to person, and children are less likely
than adults to develop symptoms. Symptoms typically “include fever, malaise, loss of
appetite, diarrhea, nausea, abdominal discomfort, dark-coloured urine and jaundice (a
yellowing of the skin and whites of the eyes)” (WHO, 2013, p. 1). There is currently no
treatment for HAV; however, therapy may be used to reduce loss of fluids and infected
individuals are encouraged to maintain a healthy diet (WHO, 2013).
To prevent the spread of HAV, countries should implement improved measures of
sanitation and food safety. In addition, vaccinating the population against the virus will
decrease the number of people who become infected. There are currently several vaccines
available worldwide, but children are not recommended for vaccination until they are at
least one year of age (WHO, 2013). NDDIC (2013) advocates that children receive the
vaccine between 12 and 23 months of age. One dose of the vaccine should be sufficient
7

to prevent the virus; however, some countries such as the United States recommend two
doses of the vaccine. These doses are given at different intervals of time. The likelihood
of contracting HAV depends on whether HAV is prevalent and if the country offers
vaccinations against the virus. The availability of the vaccine is largely determined by the
rate of hepatitis infection. Areas with high rates of infection are more likely to offer the
vaccine than areas that have a low prevalence of infection. To reduce HAV transmission,
WHO (2013) recommends raising awareness of hepatitis causes, prevention, and
treatment.
Hepatitis B Virus
Hepatitis B virus (HBV) is spread primarily through three pathways including
mother-to-child, intravenous drug use, and sexual transmission (WHO, 2013). Those who
received a blood transfusion prior to 1987, before safety measures were implemented,
may also be at risk (NDDIC, 2011). There are two stages of HBV infection: acute and
chronic. Those at the greatest risk for acute HBV include people who have undergone
transplants, intravenous drug users, sexual partners of HBV carriers, health care workers,
travelers, and people with multiple sexual partners. Unlike HAV, HBV can progress to a
chronic condition such as liver disease, cirrhosis of the liver, and cancer. Chronic HBV
affects nearly 240 million people around the world. Prevalence rates are highest in parts
of sub-Saharan Africa, East Asia, the Amazon, Eastern Europe, and Western Europe.
Chronic HBV is distinguished from the acute phase when the infection persists longer
than six months. An estimated 600,000 people die each year as a result of diseases caused
by HBV (WHO, 2013).
8

A person infected with HBV may be completely unaware they have the virus
because it is inactive for the first 30 to 180 days. The symptoms for acute HBV are the
same as HAV. They include jaundice, nausea, vomiting, abdominal pain, fatigue, and
dark colored urine. However, many infected with the virus do not experience noticeable
symptoms of acute HBV and may be unaware of their illness. Those most likely to
progress to chronic HBV are children who contract acute HBV early in life. HBV
advances as a child ages and the virus can escalate to chronic HBV later in life. The
majority of infants who become infected will likely advance to chronic illness either
during adolescence or adulthood. Adults who become infected during adulthood are not
likely to develop chronic illness; less than one in four people who develop HBV during
adulthood advance to the chronic phase. To prevent infection, people are encouraged to
be vaccinated against the virus. The HBV vaccine is 95% effective and has been shown
to maintain its effectiveness for at least 20 years. Less than 1% of people who receive the
vaccine will ever develop chronic HBV (WHO, 2013). Therefore, it is important for
people to get vaccinated early.
To assess whether a person is infected with HBV, physicians look for the
biomarker hepatitis B surface antigen (HBsAg) which indicates the presence of the
hepatitis virus. Those with acute hepatitis have both HBsAg and immunoglobulin M
(IgM) present. The test to look for these indicators involves analyzing a blood sample
from the person in question. People with chronic hepatitis who have been infected for
more than six months will have the presence of antigen HBdAg and possibly HBeAg,
which indicates the severity of the contagion (WHO, 2013). Like HAV, there is no cure
for acute HBV but forms of therapy are used to reduce patient discomfort. Chronic HBV
9

can be treated using drugs such as interferon that slow the progression of the disease but
it does not eradicate the virus. NDDIC (2013) suggests using alpha interferon and
peginterferon drugs to strengthen the immune system and fight the infection. To reduce
the transmission of HBV, countries should advocate for safe sex and clean needles, in
addition to ensuring that all blood donations undergo extensive screening for hepatitis
(WHO, 2013). These are potential policies that prisons could adapt to reduce prevalence
rates.
Hepatitis C Virus
Like HBV, the hepatitis C virus (HCV) primarily affects the liver. The most
common source of HCV infection is exposure to infected blood. This exposure can occur
during birth, organ transplants, blood transfusions, or intravenous drug use. It can also be
spread through sexual intercourse and sharing personal items (e.g., razors). Health care
workers, people with liver disease, and people living with other individuals infected with
HIV are encouraged to undergo screening for HCV (WHO, 2013). In addition, screening
is recommended for anyone who received a blood transfusion prior to 1992 (NDDIC,
2011). It is estimated that three to four million people each year become infected with
HCV and nearly 150 million people worldwide suffer from chronic HCV. Approximately
350,000 people die each year as a result of HCV-related diseases. Some countries
throughout the world experience HCV rates as high as 5% of the population (WHO,
2013).
HCV is typically inactive for two weeks to six months and few people are aware
of the infection because they do not show symptoms. The minority who are symptomatic,
“…may exhibit fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark
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urine, grey-coloured faeces, joint pain and jaundice” (WHO, 2013, p. 1). HCV develops
into a chronic illness for almost four out of five people infected; of this group, 60-70%
will develop chronic liver disease, 5-20% cirrhosis, and some may die as a result of HCV.
A person who believes he or she may be infected can undergo screening for antibodies
that indicate the presence of the virus, but physicians cannot differentiate between those
with acute and chronic infection. Recombinant immunoblot assay (RIBA) and HCV
ribonucleic acid (RNA) are used to indicate the presence of the virus. Both biological
markers signal that the virus has become active in the body (WHO, 2013).
Although there are treatment options available for those infected with HCV, these
treatments are not available worldwide and are not always effective. There are six
genotypes of HCV (HCV1, HCV2, HCV3, HCV4, HCV5, and HCV6) and they each
respond differently to treatment. To effectively treat hepatitis, physicians must be aware
of the genotype, in order to decide the best course of treatment. Interferon and ribavirin
are most commonly used, and the creation of telaprevir and boceprevir has led to
additional treatment options (WHO, 2013). Telaprevir or INCIVEK is a medication to
treat chronic infections of HCV1 and should be used in conjunction with peginterferon
alfa or ribavirin. It targets the hepatitis virus as it continues to create copies and rids the
body of the virus (Vertex Pharmaceuticals Incorporated, 2013). Like telaprevir,
boceprevir works to eliminate the virus from the body. It should be used in conjunction
with peginterferon alfa and ribavirin and only attempted after previous treatment options
have been unsuccessful (Medline Plus, 2012). There is currently no vaccine to prevent
HCV; however, by minimizing risk of exposure, the likelihood of contracting HCV
drastically decreases. Regular monitoring of liver disease and treatment may reduce the
11

number of people infected. In addition, it is important to receive vaccines for HAV and
HBV to prevent co-infection with other hepatitis viruses (WHO, 2013).
Hepatitis D Virus
The hepatitis D virus (HDV) is transmitted through infected blood but only those
who are currently infected with HBV or have had HBV in the past are at risk of
developing HDV. Therefore, those who do succumb to death while infected with HDV
do not have HDV credited as the cause, but rather HBV. If a person becomes infected
with HDV, the virus will not manifest unless the individual also becomes infected with
HBV. Those infected with HDV act as carriers and can spread the virus to others;
however, no party will show symptoms of infection unless co-infection occurs. Humans
are the primary host of HDV, but in clinical trials, it can be spread to animals like
chimpanzees and groundhogs. This type of hepatitis is a global phenomenon, with the
highest rates found in Russia, Romania, and Mediterranean countries. The rate of HDV
infection typically parallels HBV infection. Those who become infected may be at risk
for developing cirrhosis and carcinoma. There is currently no treatment for HDV and
antibiotics are largely ineffective against the virus. In order to prevent infection,
vaccination against HBV is the most effective measure (WHO, 2013).
Hepatitis E Virus
The final type of hepatitis is the E virus (HEV). It was first discovered in
Afghanistan in the early 1980s and is believed to have originated from developing
nations (Kamar et al., 2012). HEV is a ribonucleic acid (RNA) virus spread through the
consumption of water or food contaminated with infected feces. The virus is most
12

prevalent in areas with poor sanitation, such as regions in Egypt, East Asia, and South
Asia (WHO, 2013). There are four genotypes of this virus, many of which can be found
in countries worldwide. Two types, HEV1 and HEV2, can only be contracted by humans;
however, HEV3 and HEV4 can also be contracted by other mammals (Dalton et al.,
2008). HEV1 is found in developing countries and can lead to widespread epidemics
(WHO, 2013). HEV1 and HEV2 are most commonly spread through contaminated water
in developing countries (Kamar et al., 2012). HEV3 is most often found in developed
countries and does not typically lead to epidemics (WHO, 2013). Both HEV3 and HEV4
have been attributed to the consumption of undercooked meat; however, the full spectrum
of animals that carry the virus is unknown. HEV4 most often occurs in Southeast Asia
(Kamar et al., 2012). Annually, within developing countries, an estimated 20 million
people become infected with HEV and an estimated 57,000 deaths result each year from
the virus (WHO, 2013).
HEV typically runs its course within four to six weeks; however, a small
percentage of infected individuals (4-5%) can develop liver failure and die. In rare cases,
the virus can become active again in people with a history of HEV. The virus gestates for
an average of 40 days and is most commonly seen in children. Infection is typically
asymptomatic, especially for children. People between the ages of 15 and 40 are most
likely to show symptoms including jaundice, decreased appetite, tender liver, abdominal
pain, nausea, and fever. An estimated 20% of expectant mothers in their third trimester
may have complications and die as a result of HEV (WHO, 2013).
There is currently no way to diagnose HEV; however, it may be discovered if
HAV has been ruled out. As with HDV, there is no treatment available. The best way to
13

prevent HEV infection is to establish standards of sanitation to ensure clean water and a
way to safely eliminate human waste. Individuals can also avoid drinking or using
untested water and refrain from consuming uncooked fruits, vegetables, shellfish, or meat
that may contain the virus. A recent vaccine was created in China to prevent HEV;
however, it is not available globally (WHO, 2013). There is currently no standardized
vaccination to prevent HEV.
Hepatitis Prevalence
The Centers for Disease Control and Prevention (CDC) have mapped the
progression of HAV, HBV, and HCV from 2000 to 2011 in the United States. The CDC
has found that the number of HAV cases declined 90% between 2000 and 2011, from
13,397 cases in 2000 to 1,398 cases in 2011 (CDC, 2011, p. 20). The CDC has also found
that HBV declined 64% in that same time period, from 8,036 cases in 2000 to 2,890 cases
in 2011 (CDC, 2011, p. 32). Unlike HAV and HBV, however, HCV has not experienced
a steady decline. Between 2000 and 2003, HCV drastically decreased from about 3,250
cases per year to 1,600 cases per year. From 2003 to 2010, the rate of HCV remained
fairly constant and little change in the trend occurred. However, between 2010 and 2011,
cases of HCV increased by over 80% from 676 cases in 2010 to 1,229 cases in 2011
(CDC, 2011, p. 50). While many of these figures appear to be low, it is important to keep
in mind that these are only the number of cases that are reported in the United States, and
some error in reporting may have occurred. There are also many cases in the United
States that are not reported because individuals are unaware they are infected or not
actively seeking treatment from a health care provider.
14

There are several demographic differences in the general population that affect
hepatitis infection including age, gender, race, and location. In general, since 2000, the
largest increases in any type of acute hepatitis infection were seen in people under the age
of 19 (CDC, 2011, p. 51). However, the majority (approximately 75%) of chronic cases
involved someone older than 40 years of age (CDC, 2011, p. 60). Those most likely to
become infected with HAV are between the ages of 20 and 29. Meanwhile, those least
likely to become infected with HAV are under age nine (CDC, 2011, p. 21). People at the
greatest risk for acute HBV are between the ages of 30 and 39. However, people between
the ages of 25 and 54 are at the highest risk of contracting chronic HBV. Meanwhile,
people between age 20 and 29 are most likely to be affected by HCV. For this age group,
the incidence rate of acute HCV infection is .75 to 1.18 cases per 100,000 people in the
population.
Regarding gender, researchers have found that males and females experience
similar rates of HAV infection, although males have slightly higher rates than females.
The average rate of HAV infection for females is .4 cases per 100,000 people in the
population compared to .5 cases per 100,000 people in the population for males (CDC,
2011, p. 22). As with HAV, males are more likely to become infected with HBV than
females. For every one female infected, 1.7 males are infected (CDC, 2011, p. 34).
Finally, when examining acute HCV, males and females are equally likely to become
infected; however, nearly two in three chronic HCV infections are found in males.
As with gender, certain racial categories are more likely to become infected with
hepatitis but the impact of race on infection varies by the type. Asian/Pacific Islanders
have the highest incidence and mortality rate for HAV. There is an estimated .84 cases of
15

HAV infection per 100,000 people in the population for Asian/Pacific Islanders, which is
greater than the rate for Caucasians (.29 cases per 100,000) or African Americans (.27
cases per 100,000) (CDC, 2011, p. 23). African Americans have the highest rates of acute
HBV infection, while Hispanics and Asian/Pacific Islanders have the lowest rates of
acute infection (CDC, 2011, p. 33). However, Asians/Pacific Islanders are most likely to
contract chronic HBV in comparison to other racial categories. The majority of acute
HCV cases (51.6%) were reported among Caucasian non-Hispanics. Caucasian nonHispanics also experience the highest rates of chronic HCV infection. Increases in HCV
infection have also been observed among African American non-Hispanics (27.3%) and
Hispanics (21.4%; CDC, 2011, p. 53). Those at the greatest risk for acute HCV infection
are American Indians/Alaskan Natives. Risk of infection is increased by engagement in
risky behavior and maintaining a residence in certain locations with high rates of
infection.
In addition to the demographic characteristics discussed above, hepatitis
infections are more likely in certain states. The average incidence rate for HAV is .4
cases per 100,000 people in the population. Individuals residing in Arizona, Vermont,
and New Jersey have the highest risk of HAV infection in the United States (CDC, 2011,
p. 18), while West Virginia has the highest HBV incidence rate (6.1 cases per 100,000
population) (CDC, 2011, p. 30). In addition to West Virginia, people born outside of the
United States have higher rates of HBV infection compared to natural born citizens
(CDC, 2011, p. 42). As of 2011, individuals least likely to become infected with HBV
resided in Montana, Vermont, North Dakota, and Wyoming; none of these states reported
any cases of HBV infection in 2011. Unlike the reports of HAV and HBV, not all states
16

currently collect information on HCV infections. As of 2011, 44 states reported
incidences of HCV to the CDC; 15 of those states reported increases in acute HCV
infection (CDC, 2011, p. 45). In order to accurately predict trends, it is important that all
states report hepatitis prevalence.
Co-infection
Some people with hepatitis experience co-infection through contact with infected
blood. Co-infection is when an individual is infected with more than one virus at the
same time. Some individuals may become infected with hepatitis and Human
Immunodeficiency Virus (HIV) or Tuberculosis (TB). Other forms of co-infection
include having multiple strains of hepatitis. Co-infection complicates the effectiveness of
treatment. It is not recommended to begin treating patients for multiple viruses
simultaneously as the treatment will be ineffective. Physicians may need to stagger
treatments, beginning treatment for one virus before proceeding with treatment for the
secondary or tertiary virus. The following sub-sections address how bloodborne
pathogens such as Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) can be
spread through similar routes of transmission as hepatitis.
Human Immunodeficiency Virus
The likelihood of becoming infected with multiple types of bloodborne pathogens
increases as individuals engage in risky behavior. Risky behavior is defined here as
participation in unprotected sex, intravenous drug use, and unprotected exposure to
infected blood. The CDC (2014a) estimates there are currently 1.1 million people in the
United States living with HIV. Those most likely to be infected are African Americans,
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intravenous drug users, men who have sex with men, and people who engage in risky
sexual practice (e.g., multiple partners or unprotected sex). African Americans are most
commonly affected by HIV and comprise an estimated 44% of those infected (CDC,
2014a).
The HIV virus can be transmitted through several routes: sexual contact,
contaminated needles, or blood transfusions. Areas of the body that act as pathways for
transmission include the mouth, male and female genitalia, anus, and gastrointestinal
tract. These areas of the body house mucosal membranes containing the dendritic cells
that are affected by the HIV virus. The virus then infects cells in the immune system by
weakening and destroying them, making an infected person more susceptible to other
diseases (AIDS, 2014).
HIV infection undergoes three distinct phases. The first stage of HIV occurs
during the initial two to four weeks of infection. During this period, those infected begin
to show symptoms. The symptoms may include swollen glands, rash, fever, and sore
throat. In addition to the manifestation of symptoms, the virus begins to multiply and
attack the immune system. Eventually HIV begins to transition into the latency phase,
which can endure for several decades. Symptoms of infection disappear but the virus
continues to multiply and weaken the immune system. Once the disease progresses, it
reaches the third and final stage, acquired immunodeficiency syndrome (AIDS, 2014).
The length of time between stage two and three depends on several factors including a
person’s genetics, eating and exercise habits, adherence to physician recommendations,
and the use of antiretroviral treatment. A person is considered to have AIDS when he or
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she contracts one or more opportunistic diseases (AIDS, 2014). Eventually, a weakened
immune system is unable to effectively fight off a virus.
Tuberculosis
Like HIV, Tuberculosis (TB) is one of the most widespread infectious diseases. A
person may be co-infected with Tuberculosis and hepatitis. TB is the leading cause of
death for people with HIV and is responsible for one in five deaths for those infected
(World Health Organization, 2014a). TB is caused by a bacterium that affects the lungs.
It is common in young adults and in populations in developing countries. The bacteria are
spread through inhaling the germs of an infected individual. A person with active TB can
infect an estimated 10 to 15 people each year (WHO, 2014). Those with active TB
experience mild to severe symptoms including coughing, fever, and weight loss. The
infection can be treated over a six-month period of antimicrobial drugs; however, if not
treated, it can be fatal. Co-infection of TB and HIV requires additional treatment
regimens that must be decided with a health physician (WHO, 2014). Some medicines
must be staggered so a physician may begin a regimen of antiretroviral drugs for HIV and
then wait to see how that individual is responding, prior to beginning treatment for TB.
These same considerations are necessary for individuals who are infected with TB and
HBV simultaneously (Aires et al., 2012). These are important considerations among
physicians in prison settings, especially when faced with a population that may be
exposed to risky behaviors (e.g., unprotected sex, drug use).
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Behaviors Increasing the Risk of Bloodborne Pathogens
Individuals that engage in certain risky behaviors are at an increased risk of
becoming infected with hepatitis, HIV, and TB. As discussed previously, for many types
of hepatitis, sexual contact and household contact with someone infected increases the
likelihood of infection. Working at an early education program such as a daycare, preschool, or nursery also increases opportunities for exposure. International travel outside
of the United States or Canada further increases one’s likelihood of becoming infected,
especially when traveling to areas with high prevalence rates. Engaging in risky sexual
practices, such as having multiple sexual partners or engaging in unprotected sex is
another pathway for transmission. The root cause of HIV, TB, HAV, HBV and HCV is
contact with infected blood. Therefore, it is critical for individuals that work in medical
professions (or other professions where contact with individuals at high risk of
contracting these diseases) to be cautious. People should also exercise caution when
undergoing surgery, receiving organ transplants, having blood transfusions, or engaging
in intravenous drug use (CDC, 2011).
Certain pathways of transmission are more likely to lead to infection than others.
Of the HAV cases reported to the CDC in 2011, the most frequent risky behaviors were
consumption of contaminated food or beverages and traveling outside the United States
or Canada (CDC, 2011, p. 26). Meanwhile, the most common risky behaviors for HBV
and HCV include intravenous drug use, multiple sexual partners, and undergoing surgery.
Among those who report having HCV, intravenous drug use was the most frequent risky
behavior (CDC, 2011).
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Structural Strategies to Prevent Hepatitis
There are a number of strategies at the individual and structural level that can be
implemented to prevent hepatitis. At the individual level, people can proactively engage
in health promoting behavior such as good nutrition, avoiding harmful substances, and
undergoing annual health examinations. In addition, it is advantageous to avoid risky
sexual practices like multiple sexual partners or unprotected sex. At the structural level,
institutions can create national strategies for managing hepatitis. Currently, there is a
health prevention policy in place for HAV that outlines the recommended vaccination
schedule (WHO, 2013). There are also health prevention strategies in place for
preventing HBV and HCV in the healthcare industry since these workers are more likely
to be exposed to the viruses.
Clinical guidelines have been established for managing HBV and HCV including
policies on screening and referral. Some guidelines are in place to ensure drugs to treat
hepatitis are affordable. Some drugs like inferon alpha, pegylated inferon, and temofovir
have been subsidized by the government to treat HBV and HCV (WHO, 2013). Other
drugs, including ribavirin, boceprevir, and telaprevir, have been subsidized by the
government to treat HCV (WHO, 2013). Finally, national policies seek to ensure the use
of clean needles in order to prevent the spread of disease transmitted by contaminated
needles. The national injection safety policy recommends the one time use of syringes
and refraining from sharing needles (WHO, 2013).
Hepatitis Prevention, Reducing Intravenous Drug Use
Given the high percentage of the prison population that has engaged in drug use,
it is important to closely examine hepatitis prevalence. Reducing intravenous drug use,
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specifically the use of heroin, can reduce hepatitis infections. Heroin is an opioid narcotic
that is synthesized from morphine. The National Institute on Drug Abuse found in 2011
that an estimated 4.2 million people in the United States had used heroin at least once in
their lifetime. Nearly one out of every four heroin users will become addicted. Heroin can
be used in various forms like injection, inhalation, snorting, or smoking. The results of
the drug are almost immediate. Users experience a period of euphoria followed by a
period of drowsiness (National Institute on Drug Abuse, 2013). In particular, heroin users
are at risk for contracting bloodborne infections like HIV, HBV, and HCV. These
infections can be transmitted by sharing needles and other drug paraphernalia. To treat
heroin addiction, some patients undergo methadone maintenance treatment (MMT).
MMT blocks the effects of opiates, relieves cravings, and withdrawal symptoms (CDC,
2002, p. 1). Doses of 60-120mg/day of MMT for 12 months or longer are recommended;
however, many patients leave treatment early or undergo multiple rounds of treatment
after relapses (CDC, 2002, p. 2).
Former prisoners who undergo counseling and methadone treatment in prison are
more likely than participants who undergo only counseling or receive methadone
treatment (MMT) after release to continue attending treatment programs (Gordon et al.,
2008, p. 1337). In addition, those who undergo counseling and MMT in prison use heroin
fewer times and are less likely to be involved in criminal activities post release (Gordon
et al., 2008, p. 1338). While it is ideal to treat all individuals who are infected, states and
organization must take into account how much prevention and treatment will cost.
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Cost Effectiveness of Treating Hepatitis
A number of researchers have examined the cost effectiveness of treatments for
HAV (Jacobs, Rosenthal, & Meyerhoff, 2004), HBV (Jacobs, Rosenthal, & Meyerhoff,
2004; Eckman et al., 2011; Liu et al., 2013) and HCV (Tan, Joseph, & Saab 2008; El
Khoury, 2010; Eckman et al., 2013). As of 2010, there were over 100 different drugs in
existence to treat HCV (El Khoury et al., 2010, p. 153). El Khoury et al. (2010)
conducted a literature search on the cost of treatment and found nearly 400 articles that
focused on this topic. Treatment for chronic HCV was estimated to cost between $145
and $155 per person each year (El Khoury et al., 2010). However, many of these studies
were older, which may affect the accuracy of these figures.
The cost effectiveness of screening and treatment shapes many of the United
States’ policies regarding hepatitis. Screening and treatment measures that are less costeffective may not be implemented due to budgetary reasons. The current threshold for
HBV screening is 2%, which represents the maximum percentage of the population that
could be infected and still be cost effective to treat. It would be within the means of the
DOCs to treat those infected but only if 2% or less of the population had hepatitis. Any
greater percentage of the population infected with HBV would not be cost effective. This
threshold was determined using Markov analyses, which are used to understand a series
of interdependent events. Specifically, this model examines the outcome of a series of
dependent random events over time (Didkovsky, 1996). Although the current threshold
for screening is 2%, screening populations with fewer than 2% of hepatitis infections may
also be cost effective in the correct context. Eckman et al. (2011) calculated that
screening infections in .3% of a population can still be cost effective.
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Screening involves testing a small blood sample for antigens and antibodies.
Antigens are foreign substances that affect the body like viruses and parasites. In
response to the antigens, the body begins to build up antibodies in order to eliminate the
antigens from the body (Center for Substance Abuse Treatment, 2011). People who have
elevated levels of antibodies are infected and should be diagnosable by physicians. The
type of hepatitis can be determined through screening since certain levels of antibodies
correspond to each type of hepatitis virus. The presence of antigens can also indicate
whether a person has previously been infected or is currently infected with one or more
types of hepatitis.
In order to understand the cost effectiveness of the combination hepatitis A/B
vaccine compared to the typical hepatitis B vaccine, Jacobs, Rosenthal, & Meyerhoff
(2004) created a hypothetical model. In this hypothetical model, a simulated 10,000
inmates were incarcerated at age 25 for one year with a 19% probability of reincarceration one to three years after their initial release. Of the 10,000 inmates, 35%
were theorized to have chronic HCV (Jacobs, Rosenthal, & Meyerhoff, 2004, p. 12411242). During incarceration, each inmate would receive between one and three doses of
the HAV/HBV vaccine, totaling an estimated 26,000 doses, costing $309,660 (Jacobs,
Rosenthal, & Meyerhoff, 2004, p. 1242). In this hypothetical model, inmates were
estimated to face HAV risks 450% greater than the general public, assuming up to twothirds of the inmate population used injection drugs. Similarly, risk of HBV was
predicted to be 400% greater than the general public during incarceration and 2,800%
greater following release (Jacobs, Rosenthal, & Meyerhoff, 2004, p. 1243). Areas with
high rates of HAV infection are subsequently predicted to have high rates of HAV
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infection in the incarcerated population. The use of the HAV/HBV vaccine instead of the
HBV vaccine in these locations could save an estimated $425,044 (Jacobs, Rosenthal, &
Meyerhoff, 2004, p.1244). While this figure is promising, the vaccine would be less cost
effective in areas with lower rates of HAV infection.
The cost of screening and treating HCV has also been researched (Tan, Joseph &
Saab, 2008; Eckman et al. 2013; Liu et al., 2013). Birth cohorts have different likelihoods
of contracting chronic HCV, which is an important consideration when estimating cost
effectiveness. For those in older cohorts, the cost of screening and one treatment session
is much more expensive than screening and treatment for younger birth cohorts. Therapy
is more costly for older cohorts because it may take longer to administer, especially for
individuals who have progressed forms of hepatitis. Screening in conjunction with
universal triple therapy costs $64,700 for people in their 40s, $65,700 for people in their
50s and 60s, and $179,200 for people in their 70s (Liu et al., 2013, p. 9). The cost of
HCV screening and one session of treatment per person are estimated to cost between
$44,074 and $47,287 in the United States (Eckman et al., 2013, p. 1389).
Like Eckman et al. (2013), Tan, Joseph & Saab (2008) studied the cost
effectiveness of HCV treatment using a Medline search of the following terms: hepatitis
c, treatment, cost-effectiveness, prison, pegylated-interferon and ribavirin, combination
therapy, jails, and inmates (p. 1388). Their target population included incarcerated males
between the ages of 40 and 49 who were chronically infected with HCV (Tan, Joseph, &
Saab, 2008, p. 1388). Participants were divided into two groups: those who did not
undergo a liver biopsy and those who underwent a liver biopsy before the start of
treatment. Treatment included a combination of pegylated interferon and ribavirin. The
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group that underwent a liver biopsy was divided into four groups: no fibrosis, portal
fibrosis, bridging fibrosis, and compensated cirrhosis. An average life expectancy of 75
years was used to calculate cost effectiveness. The researchers hypothesized that
treatment would be administered for 48 weeks for patients with HCV1 and 24 weeks for
patients with HCV2 and HCV3 (Tan, Joseph, & Saab, 2008, p. 1389). Combination
therapy was found to be cost effective both with and without a liver biopsy for the
majority of groups, barring those with bridging fibrosis and compensated cirrhosis that
had a life expectancy of less than ten years after the start of treatment (Tan, Joseph, &
Saab, 2008, p. 1390). However, the best way to improve life expectancy is to avoid
engaging in risky behavior.
By avoiding risky behavior like drug use, unprotected sex, and unhealthy diets,
people can begin to take their first steps in decreasing the prevalence of hepatitis. At the
structural level, policies must be in place that encourage healthy behavior and offer
solutions for people who do become infected. Policies need to be specific to each area
and take into account environmental factors that affect rates of transmission. Policies
must be tailored to each population while still operating on a cost effective budget.
Summary
As described above, certain behaviors place individuals at increased risk of
exposure to hepatitis. Unfortunately, individuals engaging in these high-risk behaviors
are often concentrated at higher levels in some locations (e.g., hospitals, poor urban
neighborhoods, certain types of alcohol and drug treatment centers). One location where
high-risk individuals may be most likely to be concentrated at high levels is prison.
Prison inmates may have particularly high levels of hepatitis, particularly HCV (often
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referred to as the secret epidemic in recent years). Despite descriptive evidence that
suggests there are a disproportionate number of hepatitis cases in prison, this population
has been largely understudied. Examining rates and consequences of hepatitis in the
prison population is necessary because inmates, given their inclination to engage in high
risk behaviors, are more likely than the average citizen to come in contact with hepatitis.
The need for policies is especially visible in the correctional population, which has some
of the highest rates of infection found within the United States. This population also
provides a unique opportunity for researchers to learn more about the disease and
implement training and policy initiatives to prevent and treat the virus. Due to the
longevity of sentences in prison, inmates are more likely to complete hepatitis treatment,
as compared to other correctional facilities such as jails, which are highly transient. Most
treatments take less than one year to complete, which is the typical minimum sentence, in
prison. It is essential to understand how to treat hepatitis in order to prevent the spread of
hepatitis to the general public.
The proceeding discussion reviews the literature about individual and structural
strategies used to prevent hepatitis. In the following section, I will discuss the prevalence
of hepatitis in both community corrections (probation) and correctional facilities (jail,
prison) in the United States. I will then examine current correctional and state practices
and policies about hepatitis screening, testing, and treatment. Finally, I will attempt to
make policy recommendations regarding treatment and testing for hepatitis among
incarcerated populations.
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CHAPTER III
LITERATURE REVIEW

Correctional Settings
When people commit crime and are found guilty, the criminal justice system must
decide an appropriate sentence. Common types of punishment include jail, prison, and
probation. There has been significant growth in the incarcerated population as well as
community supervision since the late 1970s (Klingele, 2013). Community supervision
includes probation, court ordered supervision served within the community, and parole, a
period of supervision after incarceration (Maruschak & Parks, 2012). Community
supervision can be utilized in lieu of imprisonment.
Offenders who are imprisoned can be housed in either jails or prisons, depending
on their sentence. Jails are typically operated by county law enforcement agents and are
used as confinement centers for people awaiting trials, transfer, or sentencing, in addition
to housing inmates who have been sentenced to one year or less of incarceration. Jails are
transient in nature because of the high turnover rate of inmates; most people are serving
sentences that are less than one year. These individuals are also more likely than
prisoners to interact with more people in the general public because they have short
sentences. Despite the transient nature of jails, it is still important to understand the
prevalence of hepatitis in these settings since the correctional population in general, has
higher rates of hepatitis than the overall population (CDC, 2011).
28

Prisons, on the other hand, are administered by states, by the federal government,
or by private prison corporations. Prisons house inmates who are serving sentences
longer than one year or have committed felonies (Bureau of Justice Statistics [BJS],
2014). Prisons have lower turnover rates than jails, allowing more time for inmates to
receive the necessary medical treatment. Prisons provide an ideal setting to understand
policies and treatment regimens.
Understanding hepatitis in the correctional population has become an increasing
concern because there is a growing number of drug addictions in the United States and
worldwide. In 2010, the United Nations Office on Drugs and Crime (UNODC) estimated
between 153 and 300 million people around the world used an illicit drug at least once
during the previous year. Among this population, between 15.5 and 38.6 million are
believed to have a drug addiction. The most recent report on injection drug use, published
in 2008, estimated that 16 million people worldwide are injection drug users (United
Nations Office on Drugs and Crime, 2012). These statistics highlight the need to prevent
infectious diseases in drug users.
Hepatitis Prevalence in Jails
It is difficult to administer tests and treatment to jail inmates because of the
relatively short time frame that inmates are incarcerated. In a 2004 report by the CDC,
jail inmates were found to be less likely to complete the HBV vaccination series than
prison inmates. Using a sample of 889 inmates incarcerated from 1998-1999 in Texas
Correctional Facilities, HBV prevalence was assessed. Of those sampled, 18% tested
positive for HBV (CDC, 2004, p. 681). Based on these findings, 426 inmates from a
Texas jail and prison were eligible for vaccination. Of these individuals, 319 inmates
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were offered the vaccine and 125 state prisoners and 99 jail inmates accepted. The threedose vaccination series was completed by 96% of state prisoners and 54% of jail inmates
(CDC, 2004, p. 682). This finding supports the notion that vaccination in prisons may be
more feasible than in jails because it takes several months to complete the vaccination
series. Prisons must also take into account the size of the correctional population,
hepatitis prevalence, and the amount of time necessary to effectively treat hepatitis.
Prison Population Demographics
At the end of 2011, there were 10.1 million people incarcerated around the world.
The United States had the highest prison population rate as of December 2009; at yearend
2009, there were 2.29 million people incarcerated in the U.S., a rate of 743 per 100,000
U.S. residents (Walmsley, 2011). In fact, the prison population has increased in more
than two-thirds of all countries since the late 1990s (Fazel & Baillargeon, 2011).
Nevertheless, the U.S. appears to be on a different trajectory. Carson and Golinelli (2013)
reported that the United States prison population in 2012 declined for the third year in a
row from 1,599,000 to 1,570,400 inmates. The number of inmates admitted in 2012
totaled 609,800, which was the smallest cohort to be imprisoned since 1999 (Carson &
Golinelli, 2013, p. 2). State prisons also had 6.5% more unconditional releases (e.g.,
released without parole) in 2012 than 2011; in 2012, there was also a decrease in the
number of individuals sentenced to prisons for drug convictions, down 66% from the
previous decade (when drug offenders made up the largest group of new entrees into the
correctional system; Carson & Golinelli, 2013). Incarceration for drug offenses, including
distribution and trafficking, decreased by 19% between 2006 and 2011 (Carson &
Golinelli, 2013, p. 7).
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Each year, African Americans and Hispanics are disproportionately represented in
the criminal justice system. Of those convicted for drug offenses in 2011, 42% were
African American and 38% were Caucasian (Carson & Golinelli, 2013, p. 11).
Furthermore, compared to Caucasian males, African American males were six times
more likely and Hispanic males were two times more likely to be incarcerated (Carson &
Golinelli, 2013, p. 25). Similar patterns can be seen for female offenders. African
American females were three times more likely and Hispanic females were two times
more likely to be incarcerated than Caucasian females in the same age group (Carson &
Golinelli, 2013, p. 25). The relationship between race and incarceration does not appear
to be age related. As of December 31, 2012, 2.8% of African Americans, 1.2% of
Hispanics, and 0.5% of Caucasians were incarcerated in the United States (Carson &
Golinelli, 2013, p. 25). These figures represent all known offenses.
In order to understand hepatitis prevalence, it is important to study populations
that have been convicted of drug offenses, and to explore how their risky behavior can
contribute to the growing hepatitis rate in prison. Many inmates are intravenous drug
users (IDUs) prior to their incarceration and some continue to gain access to drug
paraphernalia while incarcerated (Carson & Golinelli, 2013). Most new cases of HCV
infections occur among injection drug users, and this population makes up the largest
group infected with HCV (Edlin, 2003). Unfortunately, little information exists about the
extent of injection drug practices within United States prisons. To understand the risk of
hepatitis among the incarcerated population, researchers have examined a variety of
correctional settings.
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Hepatitis Prevalence in Prison
Given its important place in the correctional system, a number of researchers have
examined chronic illnesses in prison. Using data from the 2004 Survey of Inmates in
State and Federal Correctional Facilities and the 2002 Survey of Inmates in Local Jails,
Wilper et al. (2009) analyzed the prevalence of chronic illness in jails and state and
federal prisons. The 2004 Survey of Inmates in State and Federal Correctional Facilities
was conducted between October 2003 and May 2004 and included information on 1,585
state prisons and 148 federal prisons. Of the 1,585 state prisons, 287 of 301 invited
prisons chose to participate. The 20 largest prisons were selected by the Census Bureau
during the first round of sampling and the remaining 280 prisons were chosen according
to census region and were more likely to be selected if they housed a large inmate
population. Inmates housed in state prisons were randomly selected (N=16,152), resulting
in 14,499 completed interviews. Of the 148 federal prisons, 40 were invited to participate
and 39 accepted. Federal prisons that were selected housed the largest number of inmates.
In these federal prisons, 4,253 inmates were randomly selected and 3,686 inmates
completed interviews (Wilper et al., 2009, p. 666). The 2002 Survey of Inmates in Local
Jails used a two stage sampling design; 234 jails were preselected based on large
populations of men, women, and juveniles. In the second stage, the remaining jails were
selected on occupant size. Data were collected from 417 jails (of the 465 that were
invited to participate) and 6,982 inmates (Wilper et al., 2009, p. 667).
Questionnaires asked inmates about symptoms and medical diagnoses prior to
incarceration. Medical diagnoses included HIV/AIDS, cancer, stroke, and heart problems.
In addition, inmates were asked to report any sexually transmitted diseases, cirrhosis,
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hepatitis, or kidney problems. Inmates were asked about mental illnesses, serious injuries
since imprisonment, and whether they were currently taking or had previously taken any
medications (Wilper et al., 2009, p. 667). Wilper et al. (2009) defined inmates as having a
chronic condition if they needed any follow up medical attention.
To understand the quality of healthcare in prisons, five categories were created: 1)
access to medical examination, 2) access to pharmacology, 3) access to prescription
medication, 4) access to laboratory tests, and 5) adequacy of acute care (Wilper et al.,
2009, p. 667-668). It is essential to understand the quality of medical care in prisons and
how it affects prevalence rates. Restricted access to medical care could negatively affect
hepatitis. Inmates with the greatest access to medical examinations were those with
persistent medical problems because these inmates were most in need of regular
treatment. Access to pharmacology was measured by the number of inmates that were
taking medication before imprisonment. Access to prescription medication included the
proportion of inmates that had a prescription before incarceration but were not currently
receiving prescriptions. Access to laboratory tests was operationalized as the proportion
of prisoners who needed regular blood testing. Finally, access to acute care included data
from inmates who experienced any serious injury.
The majority of inmates in state prison, federal prisons, and jails were African
American or Hispanic and younger than 35. Many inmates reported chronic medical
conditions, including 38.5% of federal inmates, 42.8% of state inmates, and 38.7% of jail
inmates (Wilper et al., 2009, p. 668). Chronic medical conditions included various health
ailments such as HIV/AIDS, heart problems, kidney problems, cirrhosis, and persistent
hepatitis.. Of those with a chronic medical disease, the majority in both state and federal
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prisons received treatment. However, 68.4% of jail inmates had not received medical
attention since imprisonment (Wilper et al., 2009, p. 669). Many of the jail inmates
reported that they were unable to obtain prescription medications that they had used prior
to incarceration during their jail incarceration.
While the compositions of other countries’ prisons are different, researchers can
still learn valuable lessons about effective or ineffective treatment. Marco et al. (2013)
examined the incidence rate and predictive factors of HCV using a sample of 119
individuals that had received treatment while incarcerated in Catalonia. The majority of
participants was male (97%), HIV negative (85%), and had a prior history of injection
drug use (81%). About one quarter of participants engaged in risky acts including getting
tattoos (8.4%), sexual acts (e.g., vaginal and anal intercourse; 5.9%), and injection drug
use (10.1%). Nine of the respondents were re-infected with HCV, and seven were
infected with a different strain of HCV (Marco et al., 2013, p. 46). Reinfection occurred
at a rate of 5.27 cases per 100 people, and was more prevalent for those who were HIVpositive as compared to HIV-negative (Marco et al., 2013, p. 47).
Rhodes, Taxman, Friedmann, and Cropsey (2008) examined the relationship
among HCV infection, gender, and criminal justice history. The study was conducted at
two prisons in Kentucky, a halfway house in Delaware, and a jail in Virginia. Participants
were tested for both HIV and HCV infection. Blood samples were drawn to test for
infection. In addition, participants were surveyed about their history of criminal offenses,
substance use, substance treatment, intimate relationships, employment, and social
demographics (Rhodes et al., 2008, p. 495). Of the 685 people invited to participate,
22.9% tested positive for HCV. Nineteen participants had mixed results and could not be
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conclusively categorized as HCV positive or negative. This group was excluded from
analyses (Rhodes et al., 2008, p. 496).
Rhodes et al. (2008) found that the overall prevalence of HCV for males and
females was 23.6%. Slightly more than half (54%) of the inmates knew they were HCV
positive before testing and were unsurprised by the test result (p. 497; 499). Those
infected with HCV had common characteristics. Injection drug use, HIV infection, HBV
infection, blood transfusions, and unprotected sex were positively associated with HCV
infection. Despite engaging in risky behavior, some offenders that tested positive for
HCV were involved in substance abuse treatment. Males were more likely to be in
treatment than females, often for cocaine or heroin use (Rhodes et al., 2008, p. 499).
HCV positive females were more likely to use cocaine than males, as opposed to heroin
use, which was more frequent among males. Females were more likely to sell sex as a
main source of income compared to males who were more likely to rely on selling drugs
for their income (Rhodes et al., 2008, p. 498). Injection drug use, unsafe sexual practices,
and multiple partners were all predictive of hepatitis infection.
Nijhawan, Salloway, Nunn, Poshkus, and Clarke (2010) randomly selected 100 of
the 251 women housed at the Rhode Island Department of Corrections (DOC) to
determine the preventative needs of incarcerated women. The participants were sorted
into three groups: those incarcerated for their first offense (32%), second to fifth offense
(35%), and six or more offenses (33%). More than half of participants reported they did
not have healthcare prior to incarceration. When asked about the vaccination for HAV
and HCV, almost half of the participants reported completing the vaccine series. The
majority of the females surveyed (70%) reported previous testing for HCV and 37% had
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tested positive (Nijhawan et al., 2010). Of those testing positive, 54% had completed the
vaccines for both HAV and HBV. No information was provided on whether the inmates
had received the vaccine before or after HCV infection. Among the individuals who were
unvaccinated, 67% were interested in receiving the vaccine (Nijhawan et al., 2010, p. 19).
Women were more likely to have completed the vaccines for HAV and HBV if they had
been tested for HCV, which was predicted by alcohol and drug use (Nijhawan et al.,
2010, p. 20). Participants who used alcohol and drugs were more likely to have sought
testing for HCV. After being tested, this group was more likely to begin the vaccination
series for HAV and HBV.
Kim, Nagami, Borch, Bowen, Lauer, and McGovern (2013) wanted to understand
racial differences in acute HCV rates among newly incarcerated prisoners. They
examined data from 12,297 inmates at Massachusetts Correctional Institute-Concord for
males and Massachusetts Correctional Institute-Framingham for females. About half of
the inmates (52%; n = 6342) underwent health assessments within their first week and
55% were screened (Kim et al., 2013, p. 947). Of the 171 identified as high risk, 138
underwent laboratory testing and 35 were identified as having acute HCV (Kim et al.,
2013, p. 948). Of the 35 participants with acute HCV, 30 reported sharing needles or
having a new partner; the remaining participants reported using other drug paraphernalia
(Kim et al., 2013, p. 948). The highest rates of infection were found among young
Caucasians. Through screening, approximately one out of every 100 inmates was
diagnosed with acute HCV (Kim et al., 2013, p. 949).
Zucker, Choi, and Gallagher (2011) used a sample of 202 participants recruited
from a county jail, community corrections program, homeless shelter, and outreach center
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for injection drug users in Western Massachusetts. Slightly more than half of participants
(57%) had not undergone the vaccination series and were at risk. About one in three
participants (29%) tested positive for HCV; the most frequently reported risk factor was
injection drug use and 83.3% of those actively using injection drugs were positive for
HCV (Zucker et al., 2011, p. 30). A follow up examination of the original participants
found vaccination series completion rates ranged from 31.6% to 38.6%. Completion rates
were consistent in all of the research sites except the outreach center for injection drug
users. Participants at the outreach center were less likely to have completed the
vaccination series (Zucker et al., 2011, p. 31). Those actively using drugs, sharing
needles, or receiving treatment for alcoholism or drug abuse were more likely to test
positive for HCV. Although there is not currently a vaccination for HCV, it is still
important to vaccinate individuals for HAV and HBV in order to reduce the number of
individuals who are co-infected.
Vaccinations in Prison
Christensen, Fisker, Krarus, Liebert, Jaroslavtsev, Christensen, and Georgesen
(2004) evaluated the efficiency of an accelerated schedule for HBV vaccination
compared with the standard vaccination measures. Accelerating HBV vaccinations would
be important for reducing prevalence at a faster rate. It is currently recommended that
children under the age of eight receive two doses at least four weeks apart. Meanwhile,
adults over the age of 18 should receive three doses over a six-month period. Adults must
wait at least four weeks in-between dose one and two and at least eight weeks between
the second and third doses. An accelerated schedule for adults is offered with the vaccine
Twinrix, which is a combination hepatitis A and B vaccine (CDC, 2014).
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The prisoners (n= 1,100) in the study location, Copenhagen Prisons, volunteered
for the first HBV vaccine. Only those with HBV were excluded from the study
(Christensen et al., 2004, p. 3898). For comparison purposes, the study was replicated in
Denmark and Estonia. In Denmark, 72 prisoners with a history of injection drug use
received the first dose of the vaccine series, though only 34 continued the series, as the
other 38 participants had a prior HBV infection (Christensen et al., 2004, p. 3899). Of the
566 prisoners in Estonia, blood samples confirmed 42% (n = 228) were positive for one
or more of the markers of HBV (Christensen et al., 2004, p. 3899). Four out of five
inmates (n = 457) in the original sample completed the vaccination series in Estonia and
42% (n = 236) received the seven month booster shot (Christensen et al., 2004, p. 3899).
Those testing negative previously were retested and 26 were positive for HBV
(Christensen et al., 2004, p. 3899).
The Impact of Hepatitis after Release from Prison
Upon release, many inmates lack any type of medical insurance. Consequently,
those undergoing medical treatment while incarcerated are often unable to continue
treatment post release (Springer, 2010). People who emerge from prison with hepatitis
can spread the disease to other people in the general population. In order to understand
inmate risk behavior, Sieck and Dembe (2011) collected blood samples from inmates
about to be released and distributed a survey to assess behavioral risks. Of the 916
prisoners that volunteered a blood sample, 16 new cases of HCV were discovered (Sieck
& Dembe, 2011). If this analysis had not been performed, inmates may have reentered
society and unknowingly exposed others to hepatitis. To understand these new cases of
HCV, researchers compared lab analyses to survey responses. Of the 744 inmates who
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completed the survey, 12.1% reported engaging in sexual acts while incarcerated, 36.5%
received a tattoo, and 1.6% used heroin during their current sentence (Sieck & Dembe,
2011). Of those who said they had received a tattoo while incarcerated, only 40.2%
cleaned the needles beforehand (Sieck & Dembe, 2011).
Previous research (Reindollar, 1999; Verger et al., 2003; Bird & Hutchinson,
2003) found that recently released parolees have an elevated risk of HBV and HCV
infection. This risk period occurs after each release. Based on these findings, Macalino,
Vlahov, Dickinson, Schwartzapfel, and Rich (2005) examined the incidence of HBV and
HCV among recidivists housed at the Rhode Island DOC. Of the 297 women in the
study, 29% were infected with HBV and 40% were infected with HCV (Macalino et al.,
2005, p. 1000). Two in three respondents were Caucasian and many had a history of
alcohol or drug use and were previously incarcerated. While examining drug use among
those infected with hepatitis, heroin and other forms of injection drugs were commonly
mentioned. Hepatitis infection was positively associated with heroin and/or injection drug
use (Macalino et al., 2005, p. 1000). This finding allows researchers to more accurately
determine which individuals are most susceptible to hepatitis infection.
Hepatitis Testing in State Prisons
As of 2000, two-thirds of state prisons had a HBV vaccination policy (n = 1,033),
but one in three did not (n = 499; Beck & Maruschak, 2004, p. 3). Each state had their
own policies; however, there was some variation between prisons in the same state.
While 1,033 state prisons had a policy to provide HBV vaccination, only 401 facilities
actually administered the vaccine (Beck & Maruschak, 2004, p. 1). The Bureau of Justice
Statistics reported that a similar percentage of state correctional facilities (70%, n = 1104)
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had a policy to test for HCV. Another 9% of facilities tested more broadly (Beck &
Maruschak, 2004, p. 1). The majority (69%) of state prisons focus on testing inmates who
fall into a targeted group, comprising inmates who were considered high risk, requested
testing, or had been referred by a physician (Beck & Maruschak, 2004, p. 2). In general,
few state facilities test inmates at the start of incarceration (n=61; Beck & Maruschak,
2004, p. 3).
In the United States, 23 states reported testing more than 500 inmates between
1999 and 2002, suggesting that there are thousands of inmates tested for hepatitis each
year. Despite these figures, the number of people imprisoned still exceeds the number of
people that there are tested. As the inmate population has increased, so too have rates of
hepatitis. As of 2000, five states described HCV rates greater than 5% of the population
(Beck & Maruschak, 2004, p. 2).
As the research reviewed in this section has demonstrated, while prisons
throughout the world have taken some steps to reduce chronic illnesses among their
populations, there is still a lot of room for improvement. Establishing comprehensive
policies in prison may be the first line of defense against both hepatitis and other chronic
illnesses Policies mandating vaccines, screening, and treatment for inmates are vital to
reducing hepatitis prevalence. To explore the impact of policies on hepatitis, in the next
chapter, I use the Ecological Perspective in an attempt to explain the decisions
policymakers make when considering hepatitis policies and practices in prisons. This
perspective examines the effect of individual, community, social, and economic factors
that impact policies in a variety of contexts. This work extends that perspective to
hepatitis policies in prisons.
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CHAPTER IV
THEORETICAL FRAMEWORK

There are numerous individual and structural factors that affect access to health,
engagement in health behavior, and health consumption. To understand factors that affect
hepatitis policies and practices in prison, I will examine individual, community, and
institutional factors using aspects of the Ecological Perspective (Kaplan, Everson, &
Lynch, 2000). The Ecological Perspective was created within the field of Epidemiology,
a field that attempts to understand the root causes of disease. For this perspective, key
factors that are assessed for each disease include individual risk factors, social
relationships, living conditions, neighborhoods and communities, institutions, and social
and economic policies. Finding the cause of a disease is complicated because there are
numerous factors that could play a role, and these factors are often interdependent (Galea,
Riddle, & Kaplan, 2010).
Kaplan, Everson, and Lynch’s (2000) Ecological Perspective: A Multilevel
Approach relies on multilevel analysis to understand how the aforementioned factors can
exacerbate or reduce risky behavior. The authors argue for a health approach that
considers individual and societal level behavioral, economic, and social factors. This
theory posits that positive and negative health behaviors cannot be attributed to any one
source. To my knowledge, no empirical studies have tested this perspective; therefore,
this study is the first of its kind to use the Ecological Perspective to understand hepatitis.
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There are many individual risk factors that influence health and wellness
including race, class, and geographic location and these factors impact likelihood of
infection with hepatitis as well. Age, birth origins, race, and sex all impact the likelihood
of becoming infected (CDC, 2011). Previous health studies have examined the effects of
individual variables but these components alone have been unsuccessful in explaining the
heterogeneity in health and wellness (Kaplan, Everson, & Lynch, 2000). Findings such as
these suggest there are other factors that must be accounted for. Kaplan, Everson, and
Lynch (2000) argue that by studying multiple factors that affect health decisions,
researchers obtain a better grasp on causes of health disparities. In the current study,
characteristics of the inmate population are being studied alongside institutional policies
and budgets that can have an effect on inmate health. Kaplan, Everson, and Lynch (2000)
divide predictors of individual behavior within the larger structure of society across five
different contexts. Each of those contexts is discussed below.
Individual Risk Factors
The decision to engage in risky behavior is affected by one’s beliefs and behavior.
Individual risk factors include a person’s consumption habits and physical behavior. In
the context of hepatitis, a person who engages in intravenous drug use, unsafe sex, or is
exposed to infected drug paraphernalia is at increased risk for hepatitis (WHO, 2014).
Other individual characteristics that increase the likelihood of disease include a person’s
attitude, coping ability, and personality (Rimer & Glanz, 2005). A negative state of mind
weakens the immune systems and increases the probability of contracting disease.
Specifically, when a person experience anxiety, their immune system is weakened and
more susceptible to disease (Massoglia, 2008).
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Social Relationships
Social relationships (e.g., networks and communal support) also affect risky
behavior. Strain may occur as a result of unhealthy relationships or situations when an
individual may be overwhelmed by the number of roles they are expected to fulfill
(Kaplan, Everson & Lynch, 2000, p. 73). Social relationships in prison are shaped
according to community factors that positively or negatively affect engagement in risky
behaviors (Smedley & Syme, 2000, p.72). The prison environment may inadvertently
expose inmates to conditions, individuals, and relationships that promote risky behavior.
Inmates could be surrounded by others who engage in risky behavior, such as needle
sharing and unprotected sex, which increases their exposure to infection. Conditions such
as these may contribute to the higher incidence rate of hepatitis in prions as compared to
the general population.
Living Conditions
Living conditions are a reflection of residential communities and the quality of
housing (Kaplan, Everson, & Lynch, 2000, p. 72). Living conditions need to be taken into
account before and during incarceration. Areas that have a greater number of intravenous
drug users and people engaging in risky behavior can negatively impact health behavior.
This may explain why some races are more likely to have hepatitis. The operating
capacity of prison facilities may also inadvertently increase hepatitis rates. In situations
when the prison is operating at or above capacity, multiple inmates may be housed within
one cell. As a consequence, health can be negatively affected because of constraints on
living conditions that exist in prisons (Smedley & Syme, 2000, p. 72). This exposure to
cell mates can increase exposure to sex, needle sharing, and other risky behaviors.
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Neighborhoods and Communities
The neighborhood or context of the community can have significant implications
on hepatitis prevalence (Kaplan, Everson, & Lynch, 2000). Certain communities, like
neighborhoods with higher proportions of low socioeconomic status residents, would
have higher rates of hepatitis because residents are exposed to conditions that adversely
affect health. Neighborhoods with large populations of nonwhites and foreign born
residents can also increase hepatitis rates in prison because these groups are not only
more likely to be affected by hepatitis but are also more likely to be incarcerated (CDC,
2011). Many people that live in urban areas are not only going to be exposed to a wide
variety of deviance but are also more likely to be arrested. Therefore, people from urban
areas that already have a higher risk of hepatitis may bring these health problems into the
prison system.
Institutions
An institution is an organization that is established for a particular purpose, such
as education. The purposes and operating procedures of an institution may positively or
negatively affect risky behavior. Institutions are directly tied to policies that shape and
maintain them, and it is important to understand how prisons affect the environment. In
regards to prison as an institution, this organization controls inmates’ schedules, their
living quarters, recreation, work detail, and privileges (e.g., visitation). Inmates housed in
prisons live in regulated settings that encourage conformity and discourage deviance.
Inmates’ interactions are constrained by the physical environment they are housed in and
reinforced by guards and staff members that regulate their activities. Rules and
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regulations within the facility strongly discourage deviant behavior and promote
conformity (Rimer & Glanz, 2005, p. 11).
Ingram and Clay (2000) discuss the importance of formal and informal rules that
structure institutions. Formal rules include articles such as laws and edicts that
consequently affect the environment. The existence of these rules, though, is not enough;
they must also be enforced (Ingram & Clay, 2000, p. 530). Without formal rules,
enforcement of prescribed norms would be difficult to maintain because the threat would
be insufficient. Informal rules are conditioned on the premise that sanctions and rewards
are agreed upon (Wolfson, 2001). Despite institutional rules that prohibit inmates from
engaging in risky behaviors, like drug use, some inmates still engage in these behaviors.
Social and Economic Policies
At all levels (e.g., institutions, cities, and states), policies may be one of the most
influential determinants of health. Social policies affect all institutions in a particular
jurisdiction and every person that lives in a jurisdiction is affected by the policies that are
in place. Social policies that effect access to medical care affect the distribution of health
problems (Kaplan, Everson, & Lynch, 2000, p.70). For example, the creation of policies
to enable intravenous drug users to have access to clean needles may reduce diseases
spread as a result of unsterilized needles.
Economic policies are defined as programs or rules that affect financial resources
(e.g., employment, taxation). Like social policies, economic policies also directly affect
how disease prevention and management is regulated (Rimer & Glanz, 2005). Inside of
the prison system, economic policies stipulating the amount of money that is dedicated to
particular medical treatments and preventions can significantly decrease prevalence rates
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of infectious diseases, like hepatitis. States must create their yearly budget with the intent
to provide certain amounts of money to areas like screening, testing, and treatment.
Economic policies affect the way resources are used and the comprehensiveness of their
design can affect prevalence rates of disease.
States with comprehensive policies can decrease cases of infection by eliminating
risky behavior from the prison population. Policies designed for infectious disease
treatment should be specific and cover essential issues of concern including vaccinations,
screening, education, and treatment. Mandatory screening for hepatitis would ensure that
illnesses are caught early and targeted prevention strategies, used as needed, would
further decrease illnesses in the prison population. Improvements in policies and their
comprehensiveness should be continually reviewed. Hepatitis, especially C, is an area of
particular concern because there is no vaccination and treatments can be time consuming
and costly (Smedley & Syme, 2000).
Summary
The Ecological Perspective originated in the field of Epidemiology and originally
focused on the causes of disease and health trends. The Ecological Perspective examined
how numerous factors shape an individual’s health. The aim of this perspective is to
understand the causes of disease, and how individual and institutional factors affect
health. By understanding the causes of a disease, researchers can find ways to reduce its
prevalence. This framework encourages a multidisciplinary approach to understanding
health. Individual choices and the community environment affect health and healthcare
decisions, in additional to institutional policies shaping individual choices. Institutional
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policies are fluid structures that are affected by state actors and current social problem
and thus can be amended when the need arises.
Of primary concern to this study is the escalating problem of hepatitis in the
United States. This increase is a driving force behind the creation, adaptation, and
expansion of current hepatitis policies in the general population and correctional facilities
that cannot be explained by factors at any one level. Consequently, the ecological
perspective’s multi-level approach may provide insight into hepatitis policy decisions.
The hypotheses presented below are derived from both the research conducted around
hepatitis in general, and the ecological perspective in particular.
Hypotheses
Based on the previously reviewed literature, 10 hypotheses were constructed.
Half of the hypotheses focused on understanding policies in prison and the remaining
examined the prevalence of hepatitis. The hypotheses are listed below.
Regarding policy:
H1

States with higher rates of hepatitis in the civilian population will be more

likely to have more comprehensive hepatitis policies in corrections.
There are more people infected with hepatitis in prison than in the general
population. As a result, states that have high rates of hepatitis in the general population
are predicted to have even higher rates of hepatitis in prison. In order to decrease the rate
of hepatitis, prisons would need to establish policies to stop infection. Two-thirds of state
prisons have policies in place (Beck & Maruschak, 2004), and that number is likely to
rise as more people being infected. Areas where infection is common would need to be
especially vigilant in stopping the virus from spreading.
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H2

States that spend more money per capita on health care for their citizens

will have more comprehensive hepatitis policies in corrections.
States with the means to spend money on improving health will have more
financial resources to dedicate to stopping hepatitis infection. Each state’s economic
policies will determine how much money is allocated towards healthcare and in what
areas (Rimer & Glanz, 2005). States with more money per capita for health care would be
able to improve health for those in the general population and prison population. States
with more resources would be able to channel those funds into policies to prevent
infection.
H3

States with larger inmate populations will have more comprehensive

hepatitis policies.
Substantial inmate populations increase the likelihood inmates will be exposed to
and infected with hepatitis during the course of incarceration. Prisons with large
populations may be overcrowded and reduce the ability of the facility to separate healthy
inmates from infected inmates. Previous research examining Tuberculosis (one possible
co-infected disease) found high prison density increases the likelihood of infection
(MacIntyre et al., 1997). In regards to this study, large numbers of inmates increase the
chances that a person is going to be exposed to hepatitis during the course of
incarceration.
H4

States with higher levels of median household income will have more

comprehensive hepatitis policies than states with lower levels of median
household income.
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Kaplan, Everson, & Lynch (2000) find that widening social classes are associated
with the prevalence of disease. Therefore, people in the upper class should be healthier
than those in the lower class. States with higher median household incomes are predicted
to have more comprehensive hepatitis policies because residents are theorized to have
more medical resources. Households with greater access to resources are predicted to
have annual physicals, seek out needed medical treatment, and follow physician’s
recommendations. At the state level, areas with higher income will have more financial
resources to devote to developing hepatitis policies.
H5

States with lower percentages of nonwhite residents will have more

comprehensive hepatitis policies than states with higher percentages of nonwhite
residents.
Previous literature has found that rates of hepatitis A and B are greatest among the
nonwhite population. Asian/Pacific Islanders are most likely to be infected with HAV,
while African Americans are most likely to be infected with HBV (CDC, 2013, p. 23;
33). Although whites are more likely to be infected with HCV, the number of nonwhites
who are infected has been increasing (CDC, 2013, p. 53). American Indians and Alaskan
Natives are at the greatest risk of contracting HCV (CDC, 2011). These statistics suggest
that white residents may have more comprehensive hepatitis policies. Areas with fewer
minorities are theorized to have more comprehensive hepatitis policies because there may
be fewer social barriers and more environmental and socioeconomic factors that
encourage health-promoting behavior. For example, white residents may reside in
neighborhoods that promote healthy active lifestyles (Malecki et al., 2014).
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Regarding prevalence:
H6

States with higher rates of hepatitis in the civilian population will have

higher rates of hepatitis in prison.
The prevalence of hepatitis in the general population will be mirrored in the prison
population. Areas that have high rates of hepatitis in the general population will have
high rates in prison. Institutions disproportionately house more people infected with
hepatitis than in the general population. Intravenous users are particularly susceptible to
contracting hepatitis, especially hepatitis C (Edlin, 2003). As previous research has found
drug users still make up a significant portion of the correctional population (Carson &
Golinelli, 2013).
H7

States that spend more money per capita on health care for their citizens

will have lower rates of hepatitis in prison.
States that allocate money to reducing health issues are expected to have lower rates
of disease. Resources dedicated to reducing hepatitis transmission and improving testing
and treatment should affect the incidence rate. These resources are dependent upon the
existing economic policies (Rimer & Glanz, 2005). States that spend money on health
care will have lower rates of hepatitis because the general population is healthy.
H8

States with higher inmate populations will have higher rates of hepatitis in

prison.
The greater the number of people who are imprisoned, the greater the probability is
that someone will have a history of infection or currently be infected with hepatitis.
States with large inmate population may also experience overcrowding, which allows for
easier transmission (MacIntyre et al., 1997). During the course of incarceration, prisoners
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may be exposed to environmental and social conditions that weaken their body’s ability
to fight off infectious disease.
H9

States with higher levels of median household income will have lower

rates of hepatitis in prison.
States with high levels of median household income will have greater access to
medical resources. These resources enable a person to engage in health promoting
behaviors and reduce factors that would put them at risk for hepatitis infection. Positive
health practices before prison will be reflected in the rate of hepatitis in prison. Areas that
have access to medical resources are less likely to experience high rates of infection
(Kaplan, Everson, & Lynch, 2000).
H10

States with lower percentages of nonwhite residents will have lower rates

of hepatitis in prison.
Racial differences exist in exposure to the various types of hepatitis; however, in
general Caucasians are less likely to become infected than other racial groups.
Asian/Pacific Islanders are the most likely to become infected with HAV, African
Americans are most often affected by HBV, and American Indians and Alaskan Natives
are at the greater risk for HCV (CDC, 2011). These findings suggest that states with
fewer nonwhite residents will have lower rates of hepatitis.
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CHAPTER V
METHODOLOGY

Despite all the literature that is available on hepatitis prevalence in the United
States and the types of factors that affect transmission, few researchers have examined
hepatitis prevalence in the prison population and its impact on the general population.
There is also a lack of research dedicated to examining how hepatitis rates are affected by
institutional policies. To address these gaps in the literature, this study began an
exploratory effort.
I began this effort by conducting a content analysis of institutional policies
available on the 50 states’ Department of Corrections (DOC) websites. To obtain this
information, an internet search of each DOC website was conducted using key search
terms (e.g., hepatitis, communicable disease, and infectious disease). All policies were
downloaded and organized by the state to which they belonged. Some states had multiple
documents pertaining to hepatitis and related diseases.
I then conducted an internet search of the United States Bureau of Prisons (BOP)
website to determine their recommendations for reducing hepatitis in prison and
compared the BOP guidelines for hepatitis A, B, and C with available state policies to
determine the comprehsiveness of each state’s hepatitis prevention policy. To identify
hepatitis policies within each state, I used search terms such as hepatitis, viral hepatitis,
hepatitis A, hepatitis B, hepatitis C, hepatitis co-infection, bloodborne pathogens, and
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communicable disease. From the BOP guidelines, 15 criteria were selected and compared
to guidelines within each state DOC. The guidelines were selected based on broad topics
of education, vaccination, treatment, and testing. These topics were among the most
widely discussed information in the literature surrounding hepatitis and hepatitis in
prison.
To better understand prevalence rates, I then created and distributed a survey to
each state’s DOC (included in Appendix A). Many of the questions were derived from
previous research that had assessed communicable diseases in the early 2000s (Beck &
Maruschak, 2004). The process whereby the survey was distributed is described below.
The survey created for this study included open and closed-ended questions about
hepatitis, HIV, and Tuberculosis policies for inmates. The majority of questions were
closed-ended. This format was intended to cut down on the time participants would need
to complete the survey. Previous research has suggested closed-ended questions allow for
faster participant responses, easier comparison during data analysis, and would enable
respondents to be more open about sensitive subjects (Neuman, 1997). Open-ended
questions were intended to reveal more information about a given topic and to allow
participants to clarify their responses (Neuman, 1997).
The decision to use an online survey was made after investigating literature on
different survey methods. Previous research (Manfreda, Bosnjak, Berzelak, Haas, &
Vehovar, 2008) suggested that web based surveys have the potential to produce data that
is comparable to mail based surveys, despite the perception that online survey response
rates are much lower. Online surveys are more economical to distribute, and funds, if
available, may be reallocated to improve response rates (Manfreda et al., 2008, p. 98).
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The intended target group, government employees, generally has access to the Internet
(Dillman, 2000, p.356). Therefore, difficulty accessing the survey would not pose an
issue.
Before distributing the survey, I contacted a representative at each state DOC to
explain the purpose of my study and my research questions. In order to identify a contact
person, I began by using an Internet search of departments within each DOC. While I
believed that contacting the department of health services would be the best approach,
contact information (email or telephone number) was not always provided. In some
situations, the first point of contact was the general information number for all DOCs. By
calling this number, I was referred to either to a department, often something akin to
health services, or a specific representative who would likely know the information I was
requesting. After I had received this information, those departments and/or individuals
were contacted, although there were varying rates of success.
During the first week of data collection in early August 2014, I called all 50
DOCs but had only one state complete the survey over the telephone. States were given
the option to complete the survey over the telephone or be provided with a link to
complete the survey online. The survey was available through Qualtrics, a secure online
survey website that would store state responses. It was anticipated that an online survey
would be easiest for representatives to complete given their access to technology.
Qualtrics was selected in particular because this program had a number of user friendly
features (e.g., being able to go back in the survey, correct answers, and allowing for
open-ended questions).
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The initial data collection revealed a number of unforeseen issues. Participants
were able to use many of the user friendly features; however, after a participant had gone
through all of the questions, they were unable to reenter the survey. The survey included
45 questions. If a participant went through all 45, they could not restart the survey. If a
participant only went through 44 questions though, they would have been able to go back
and complete the survey. The design of this survey program was better suited for
questions that required little research, as opposed to questions that required participants
to look up answers. Due to these issues, the use of Qualtrics for data collection was
suspended after one state attempted to complete the survey and experienced difficulties
with the website. Concerns over user-friendliness led to creation of a version of the
survey that could be completed on their word processing program instead of at the
Qualtrics website.
During the summer before the start of data collection, I uncovered an article on
inmate health care had been published in Corrections Compendium (Carroll, 2013). The
data presented in this publication were similar to the data that I was attempting to collect
for this research, so I contacted the author of the study in late July to request use of her
data and to ask for her suggestions about contacting DOCs. She agreed to share the data
and provided a list of contacts that had either completed her survey or forwarded the
survey to the appropriate party. The list contained 38 email addresses; however, some of
those individuals no longer worked for their state agency, while other email addresses
were invalid. During my own search for contacts, when I was provided with the name of
a specific individual and was unable to speak to him/her over the telephone, DOC
websites were used to acquire an email addresses. However, email addresses were only
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available in about half of the states and, in those circumstances, I relied on the list of
email addresses provided to me to obtain a completed survey for each state.
Using the new list of contacts, I distributed surveys to each DOC in August 2014
and persisted until December 2014. The questions were constructed to elicit responses
about hepatitis, HIV, and Tuberculosis policies and prevalence. Questions included the
year each policy was first implemented, the availability of testing and treatment, and the
number of inmates that were known to have infectious disease(s) within each state DOC.
During this five month time period, states were contacted by telephone an average of six
times and by email an average of three times. States were sent follow up reminders
asking them to complete the survey throughout this period. I had more frequent
communication with some states than others, primarily due to quick email responses or
because they had specific questions about the survey. By early November, only 11 states
had partially or fully completed the survey. Unexpected policies such as prohibiting the
release of information to students and requiring reviews of research proposals further
inhibited data collection. To generate more participation, David May contacted personnel
from 15 states that had shown the most promise of answering the survey. At the end of
the data collection period, 14 states had partially or fully completed the survey. Two
states had responded by telephone, one through Qualtrics, and the remaining 11
completed an electronic or hard copy version that they returned to me via email. Due to
the unsuccessful data collection, secondary data was used instead. The limitations and
lessons learned from the data collection process are discussed later in the conclusion.
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Dependent Variables
Operationalizing Hepatitis Policies
As mentioned earlier, an Internet search revealed guidelines created by the BOP
that outlined how states should handle cases of hepatitis A, B, C, and HIV. There were
many criteria that could have been used for analyses; however, I selected 15 criteria from
the BOP guidelines because they reflected best practices in the literature on infectious
diseases. These key aspects of dealing with infectious diseases included education,
vaccination, testing, and treatment.
The guidelines for analyses included four measures for HAV, four for HBV, four
for HCV, two for co-infection, and one for HIV. States were then ranked on a scale of
their similarity to the 15 selected BOP guidelines, with scores ranging from zero (no
matching criteria) to 15 (most similar). States were given one point for each guideline
they implemented that matched federal guidelines. Failure to meet federal guidelines
elicited no points.
The 15 guidelines used for comparison are presented verbatim below.
1.

All newly incarcerated inmates should be offered voluntary HIV testing
(BOP, 2013a, p.1).

2.

Special consideration of antiviral treatment should be given to people coinfected with HBV/HCV (BOP, 2011a, p.5).

3.

Special consideration of antiviral treatment should be given to people coinfected with HCV/HIV (BOP, 2011a, p.5).

4.

BOP (2008) recommends vaccinating certain individuals for HAV including
those with liver disease, cirrhosis, clotting disorders, intravenous drug users,
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males who engage in same-sex practices, and those at risk during a HAV
outbreak (p.8).
5.

Any inmate that displays symptoms of hepatitis A should be tested (BOP,
2008, p.2).

6.

Inmates that are confirmed to have acute HAV should be isolated in order to
avoid contagion; which can last up to two weeks from the onset of symptoms
(BOP, 2008, p.2).

7.

An inmate with HAV should be monitored daily even though there currently
is not an effective treatment (BOP, 2008, p.3).

8.

At the start of incarceration, it is recommended that trained personnel provide
new inmates with information on HBV infection, modes of transmission,
history, and disease management (BOP, 2011b, p. 20).

9.

At the start of incarceration, it is recommended that trained personnel provide
new inmates with information on HCV infection, modes of transmission,
history, and disease management (BOP, 2011a, p. 6).

10.

High risk inmates should be screened for HBV (e.g., intravenous drug use,
pregnancy, history of STIs, elevated ALT) (BOP, 2011b, p.3).

11.

High risk inmates should be screened for HCV (e.g., intravenous drug use,
multiple sexual partners, previous infection) (BOP, 2011a, p.3).

12.

HBV vaccination is recommended for any person who falls into the high risk
category (e.g., history of STD, intravenous drug use, HBV or HIV infection,
tattooed in jail) or under the age of sixty with diabetes (BOP, 2013b, p.11).
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13.

It should be determined whether HBV treatment is necessary and the
recommended approach (BOP, 2011b, p.5).

14.

Before treating HCV, physicians must determine the genotype of the virus
which affects the most effective course of antiviral treatment (BOP, 2011a,
p.5).

15.

Inmates with confirmed HCV are recommended for treatment (e.g.,
intravenous drug use, multiple sexual partners) (BOP, 2011a, p.5).
Hepatitis policies in each DOC were compared to the BOP guidelines for HAV,

HBV, HCV, HIV, and co-infection. Specifically, I looked for consistency in themes to
understand similarities and differences between state DOCs and the BOP guidelines. For
example, the BOP (2011a) guidelines suggest that inmates should be provided with
information about HCV infection. In each state’s DOC policies, I looked for any mention
of providing information to or educating inmates about HCV infection. If any mention of
HCV education was included in the state policies, the state received one point for that
criteria.
Operationalizing Hepatitis C Prevalence
Of particular concern among types of hepatitis is the growing number of HCV
infections. Unlike either HAV or HBV, there is no vaccination to strengthen immunity
against this virus. While people who engage in risky behavior are most likely to become
infected, this virus has the potential to spread to other groups in society. To understand
HCV prevalence, rates in the inmate population were analyzed. These rates come from
the Carroll (2013) described earlier. Carroll reported data on inmate health care and
communicable diseases, including HCV. Of the 38 states that completed the survey, 37
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had a record of the number of HCV infections. The percentage of HCV prevalence within
the inmate population was also reported (Carroll, 2013, p. 17). These data became the
second dependent variable and are reproduced in Table 1.
The data presented in Table 1 demonstrate the prevalence of HCV in prison
derived from Carroll’s (2013) research. In the survey, states were asked to estimate the
percentage of the total population with HCV. Of the 31 states with available data, Kansas
(1%), Nevada (1.5%), and New York (1.6%) had the lowest HCV prevalence. New
Mexico (45%) and Alabama (25%) had the largest percentages of prisoners infected with
HCV.
Independent Variables
Secondary Data Collection
The data described above were merged together in one spreadsheet and then
analyzed in version 21 of the Statistical Package for the Social Sciences (SPSS). To test
the hypotheses for this study, I derived 14 independent variables to predict the
comprehensiveness of hepatitis policies and hepatitis prevalence in prison from the
literature review presented earlier. The operationalization and descriptive statistics for
each of these variables are presented below.
Table 2 includes four columns of information. These columns include the
percentage of the population that was foreign-born in each state, the percentage of the
state’s population that was nonwhite, the state’s healthcare expenditures per capita, and
the median household income for each state. Each measure is discussed in detail below.
The percent of the population that was foreign-born was selected because people
born outside of the United States are often more likely to become infected with hepatitis
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because they are often not vaccinated in their youth and experience poorer standards of
sanitation (CDC, 2011). Data about the foreign-born and non-white population, in
addition to the median household income, were derived from the 2010 U.S. Census
Bureau, State and County QuickFacts webpage. The data come from various Census
surveys including the American Community Survey and the Census of Population and
Housing (U.S. Census Bureau, 2014). More than half of the states (62%) had a population
that included less than 10% foreign-born inhabitants. Indiana (0%) and West Virginia
(1%) reported the smallest foreign-born populations. California (27%), New York (22%),
and New Jersey (21%) had the highest proportion of foreign-born residents.
The percentage of the population that was nonwhite was also selected because
nonwhites are more likely to be infected with hepatitis compared to whites (CDC, 2013).
These data are presented in the second column of Table 2. Approximately one in five
states (16%) had less than a 10% non-white population. States reporting the lowest
percentage of non-white residents included Vermont (5%) and Maine (5%). Meanwhile,
states reporting the greatest percentage of non-white residents included Hawaii (83%),
Maryland (40%), Mississippi (40%), and Georgia (38%).
Healthcare spending per capita is indicative of the access and quality of care
available to residents. States that spend more money on healthcare per capita may be
taking preventative measures to prevent hepatitis infection. The data about healthcare
expenditures per capita were obtained from The Henry J. Kaiser Family Foundation, a
non-profit organization concentrated on health topics. The data were originally acquired
from the U.S. Department of Health and Human Sciences (HHS). Healthcare
expenditures per capita are based on estimates from the National Health Expenditure
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Account (The Henry J. Kaiser Family Foundation, 2009). All 50 states spent more than
$5,000 per capita. States reporting the lowest expenditures were Utah ($5,031), Arizona
($5,434), and Georgia ($5,467). Massachusetts ($9,278), Alaska ($9,128), and
Connecticut ($8,654) reported the greatest healthcare expenditure per capita.
A state’s median household income is another indicator of wealth and also may
reflect something about healthcare access. In terms of median household income,
reported figures ranged from $39,622 in Louisiana to $71,322 in New Hampshire. Only
two states, Louisiana and Arkansas, reported a median household income of less than
$40,000.
HAV, HBV, and HCV rates in the general population are affected by the number
of people who have engaged in risky behavior. Rates of HAV, HBV, and HCV in the
general population (e.g., among people not serving time in correctional settings) are
presented in Table 3. These data were provided from the 2012 Viral Hepatitis
Surveillance report that is collected from the National Notifiable Disease Surveillance
System. Through this system, local and state health departments report cases of HAV,
HBV, and HCV. However, in order for information on HBV and HCV to be discussed in
the report, the CDC has to acquire permission from states (CDC, 2012).
Of the 47 states that reported HAV rates in the general population, only three
states had rates of at least 1%. These states included Arizona (1.4%), Delaware (1%), and
Michigan (1%). South Dakota was the only state to report a 0% HAV rate in the general
population. Nearly one in three states (32.6%) reported HBV rates in the general
population that had at least a 1% rate of infection. States with the highest rates were West
Virginia (7.6%), Kentucky (4.1%), and Tennessee (37%). Two states, North Dakota (0%)
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and Wyoming (0%), had the lowest rate of HBV infection. In regards to the prevalence of
HCV rates, nearly four out of five states (82%) provided an estimate of infection.
Kentucky (4.1%) had the highest rate of HCV, followed by Oregon (2.1%) and Indiana
(1.7%). Both North Dakota and South Carolina had a 0% rate of HCV prevalence.
The percentage of the DOC budget that was allocated for inmates’ healthcare and
the average healthcare expenditure (in dollars) per inmate are presented in Table 4. These
data were derived from those reported by Carroll (2013). States that allocate a larger
percentage of their budget to treating communicable diseases may cut down on hepatitis
rates in prison and the general population. The amount of money spent per inmate on
healthcare annually is also important to understand, as some inmates have more access to
care than others and had more expensive medical expenses.
Only 38 states reported the percent of the state’s total DOC budget allocated for
inmate’s healthcare. Among these, North Dakota (8%), Louisiana (9%) and Montana
(9%) had the lowest percentages. The budgetary allotment varied greatly between states,
and ranged from 8% in North Dakota to 81% in Utah. Following Utah, Alabama (24%)
had the second highest percentage of their budget allotted to healthcare. The average
annual expenditure per inmate (in dollars) was reported by only 32 states in Carroll
(2013). Expenditures ranged from $1,251 in Montana to $11,655 in Vermont. More than
half of states (20 of 32) spent less than $5,000 per inmate annually on healthcare needs.
The remaining 12 states spent in excess of $5,000, with Vermont ($11,655) and
Massachusetts ($8,457) spending the most money on individual inmate healthcare.
The size of the institutional population, the number of HIV infections, and the
HIV rate in prison using data derived from Carroll (2013) are presented in Table 5. The
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size of the prison population can have a significant impact on the rate of hepatitis.
Inmates are more likely to engage in risky practices that put them at risk, in general, for
infectious diseases. The total prison population data are based on the most recent
statistics provided by each state’s Department of Corrections. With the exception of
Hawaii, all population counts were taken from 2014 annual reports, posted online in June
2014. The data for the prison population in Hawaii were drawn from the most recent
annual report available online, published in 2012. The number of residents housed in
each Department of Corrections varied greatly, from 1,576 inmates in North Dakota to
150,784 inmates in Texas (these figures pertain only to facilities within the state, and not
contracted facilities). States reporting the lowest correctional population include North
Dakota (N = 1,576), Vermont (N = 2,096), and Maine (N = 2,204). States with the largest
correctional populations are Texas (N = 150, 784), California (N = 115,824), and Florida
(N = 100, 884).
The data presented in Table 5 also reflect the number of inmates known to have
tested positive for HIV as reported in Carroll (2013). In cases where the DOC estimated
the number of cases and provided a range of numbers, the median value was used for
these analyses. The HIV rate in prison was calculated using the number of HIV infections
reported by Carroll (2013) divided by the prison population for each state. This number
was then multiplied by 100,000 in order to calculate the rate of HIV per 100,000 inmates
(Number of HIV infections/Prison population*100,000).
Carroll (2013) included data on the number of HIV infections reported for 37
states. Two states, New York (N = 2,950) and Texas (N = 2,261) reported greater than
2,000 HIV infected prisoners in the state. One in three states (13 of 37) reported less than
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100 cases of HIV infections in prison; the state reporting the fewest HIV infections in
prison was North Dakota, with five cases of HIV infection. Given the varying size of the
correctional population in the United States and the number of known HIV infections,
there were a wide range of HIV rates in prison. New Mexico (120 per 100,000) had the
lowest HIV rate in the prison population while New York (5,449 per 100,000) and
Louisiana (2,798 per 100,000) had the highest rates of HIV infection.
Table 1

Hepatitis C Prevalence in Prisons

State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri

% Hepatitis C in Prison
25
N/A
16.8
10
N/A
11
N/A
N/A
N/A
N/A
5
N/A
N/A
11
N/A
1
3
2.1
N/A
9
17.5
N/A
N/A
N/A
13

State Index
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

% Hepatitis C in Prison
17
9.8
1.54
35
N/A
45
1.6
N/A
20
6.9
5.6
99
12.3
N/A
2.8
1
11.5
12.4
25
N/A
N/A
19
9.63
N/A
2

Note: N/A states are missing because they were not reported in Carroll (2013)
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Table 2
State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

State Descriptive Information
% Population ForeignBorn
4
7
14
4
27
10
14
8
19
10
18
6
14
0
4
7
3
4
3
14
15
6
7
2
4
2
6
19
5
21
10
22
8
3
4
6
10
6
13
5
3
5
16
8
4
11
13
1
5
3

% Population Nonwhite
30
33
26
20
27
12
18
29
22
38
83
6
22
14
8
13
12
37
5
40
17
20
14
40
16
11
10
23
6
27
17
29
28
10
17
25
12
17
14
32
14
21
20
8
5
29
29
6
12
7
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Healthcare Expenditure
per Capita (in dollars)
6,272
9,128
5,434
6,167
6,238
5,993
8,654
8,480
7,156
5,467
6,856
5,658
6,756
6,666
6,921
6,782
6,596
6,795
8,521
7,492
9,278
6,618
7,409
6,571
6,967
6,640
7,048
5,735
7,839
7,583
6,651
8,341
6,444
7,749
7,076
6,532
6,580
7,730
8,309
6,323
7,056
6,411
5,924
5,031
7,635
6,286
6,782
7,667
7,233
7,040

Median Household
Income (in dollars)
41,381
61,137
50,602
39,919
57,528
63,371
67,781
52,219
47,886
47,439
61,408
51,767
57,196
50,553
54,855
51,485
42,158
39,622
50,121
65,262
62,963
48,801
60,907
40,850
50,311
44,132
53,774
45,369
71,322
61,782
42,127
53,843
41,208
52,888
46,398
43,777
56,307
53,952
57,812
43,749
54,453
42,499
53,027
62,967
54,842
67,620
60,106
40,241
55,258
55,700

Table 3
State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

Hepatitis Rates in the General Population
Hepatitis A Rates
(per 100,000)
0.4
0.1
1.4
0.3
0.5
0.5
0.6
1.0
0.5
0.5
0.4
0.7
0.5
0.2
0.2
0.5
0.6
0.2
0.7
0.5
0.6
1.0
0.5
0.4
0.3
0.6
0.9
0.4
0.5
0.7
0.5
0.6
N/A
0.3
0.3
0.3
0.2
0.5
0.3
0.1
0.0
0.4
0.5
0.1
0.3
0.6
0.4
0.4
0.4
0.2

Hepatitis B Rates
(per 100,000)
1.6
0.1
0.2
2.5
0.4
0.5
0.4
1.2
1.3
1.1
0.4
0.3
0.7
1.4
0.4
0.3
4.1
1.0
0.7
0.9
1.1
0.8
0.3
2.6
0.8
0.2
0.5
1.0
0.3
0.8
0.1
0.6
0.7
0.0
1.5
2.1
0.6
0.5
N/A
0.8
0.2
3.7
0.7
0.5
0.3
1.0
0.5
7.6
0.4
0.0

Hepatitis C Rates
(per 100,000)
0.5
N/A
N/A
0.2
0.2
0.8
0.9
N/A
0.6
0.8
N/A
0.7
0.2
1.7
0.1
0.6
4.1
0.2
0.6
0.7
0.6
0.8
0.6
N/A
0.1
0.9
0.2
0.4
N/A
0.8
1.0
0.5
0.6
0.0
0.1
2.1
0.9
0.5
N/A
0.0
N/A
2.0
0.2
0.6
1.0
0.9
0.8
3.0
0.5
N/A

Note: N/A states are missing because they were not reported in CDC (2012)
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Table 4

Inmate Healthcare Expenditures
State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

% Allocated for Inmate
Healthcare
24
N/A
14
18
N/A
13
14
N/A
N/A
19
10
N/A
N/A
15
N/A
17
12
9
12
22
19
16
15
15
21
9
16
17
11
14
17
13
N/A
8
16
12
N/A
12
N/A
16
15
11
15
81
13
15
16
12
N/A
N/A

Avg. Annual Health Care
Cost per Inmate (in dollars)
N/A
N/A
4,019
4,131
N/A
4,271
4,988
N/A
N/A
3,858
N/A
N/A
N/A
3,679
N/A
N/A
2,525
3,104
7,574
7,421
8,457
6,610
6,613
3,341
,602
1,251
5,659
3,348
N/A
5,703
N/A
5,809
N/A
4,309
5,143
2,683
N/A
4,839
N/A
2,889
N/A
4,311
2,928
3,396
11,655
5,195
6,184
4,606
N/A
N/A

Note: N/A states are missing because they were not reported in Carroll (2013)

68

Table 5

HIV in Prison

State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin

Wyoming

Total Prison Population
26,000
5,031
41,678
14,558
115,824
17,807
16,594
5,550
100,884
37,156
3,243
8,177
48,902
27,968
8,179
9,509
12,108
18,763
2,204
21,002
10,686
43,704
9,929
19,251
31,537
2,545
5,210
12,486
2,791
22,318
25,076
54,142
38,052
1,576
50,774
26,539
14,588
54,107
3,188
21,904
3,593
21,246
150,784
7,028
2,096
30,005
16,554
5,355
21,993
2,352

HIV Infections in Prison
(Raw Numbers)
256
N/A
184
105
N/A
135
281
N/A
N/A
845
18
N/A
N/A
166
N/A
33
78
525
N/A
456
207
397
55
212
295
9
23
176
8
387
30
2950
N/A
5
405
131
N/A
608
N/A
377
11
226
2261
33
8
323
118
31
N/A
N/A

HIV Rate in Prison
(per 100,000)
985
N/A
441
731
N/A
758
1,693
N/A
N/A
2,274
555
N/A
N/A
594
N/A
347
644
2,798
N/A
2,171
1,937
908
554
1,101
935
354
441
1,410
287
1,734
120
5,449
N/A
317
798
494
N/A
1,124
N/A
1,721
306
1,064
1,500
470
382
1,076
713
579
N/A
N/A

Note: N/A states are missing because they were not reported in Carroll (2013)
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CHAPTER VI
FINDINGS

To begin the data analysis, I used the content analysis data described earlier to
compare hepatitis policies in each of the 50 states to the 15 BOP guidelines. The results
of that comparison are presented in Table 6. As previously mentioned, using guidelines
from BOP, states were ranked from 0 to 15, with zero representing stats that did not meet
any of the BOP guidelines and 15 being states that met all 15 of the BOP criteria. North
Carolina, Pennsylvania, and Ohio had the most comprehensive policies, scoring 7 out of
15 on the index. A substantial majority of states (84%) received scores of five or less and
no states met all 15 federal guidelines. Of particular importance is the fact that 20 states
did not meet any of the guidelines.
The number and percentage of states that met each of the BOP guidelines are
presented in Table 7. The greatest number of states (36%) adhered to the guideline that
high-risk inmates should be screened for HCV. The next most frequently adhered to
policies were HIV testing of new inmates (26%) and recommending treatment for
inmates with HCV (26%). Of all the criteria, two were not included by any state. No state
policy mentioned special consideration when treating people co-infected with HBV and
HCV. State policies also did not mention the need to monitor the health of HAV positive
inmates.
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To examine the hypotheses regarding the relationship between the 14 independent
variables and both the state’s hepatitis policies and each state’s rate of HCV infection in
prison, Pearson product moment bivariate correlations were used. The results of these
bivariate correlations are presented in Table 8. Although the vast majority of variables
had no significant impacts on both dependent variables, the results suggest that the
comprehsiveness of a state’s hepatitis policies related significantly to the number of HIV
infections in prison (.331, p = .045).
States with the highest number of HIV infections had the most comprehensive
hepatitis prevention policies. The prevalence of HCV in state prisons also had only one
significant correlate. States with the higher rates of HIV in prison were significantly more
likely than states with lower HIV rates (.218; p = .079) to have higher HCV prevalence
rates in prison. The effects of these two independent variables (HIV infections in prison
and HIV rate in prison), while not statistically significant in all cases, were the two best
correlates of the state’s hepatitis policy and two of the four best correlates of HCV
prevalence in prison. Thus, HIV among prisoners has an important relationship with
HCV among prisoners in the states under study here. Interestingly, there was only a
moderate relationship between the dependent variables. While the relationship was in the
expected direction, the relationship was not statistically significant.
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Table 6
State Index
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri

Hepatitis Policies in Prison
Comprehensiveness of State Index
Hepatitis Policies (0-15)
Montana
1
Nebraska
0
Nevada
1
New Hampshire
1
New Jersey
0
2
New Mexico
3
New York
3
North Carolina
4
North Dakota
2
Ohio
0
Oklahoma
4
Oregon
1
Pennsylvania
2
Rhode Island
1
South Carolina
2
South Dakota
6
Tennessee
0
Texas
0
Utah
0
Vermont
2
Virginia
5
Washington
0
West Virginia
0
Wisconsin
0
Wyoming
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Comprehensiveness of
Hepatitis Policies (0-15)
0
0
0
4
4
2
6
7
0
7
3
4
7
0
0
0
0
2
0
0
3
6
0
5
2

Table 7

Meeting Bureau of Prisons Guidelines

BOP Guidelines
High risk inmates should be screened for HCV (e.g.,
intravenous drug use, multiple sexual partners,
previous infection)
All newly incarcerated inmates should be offered
voluntary HIV testing
Inmates with confirmed HCV are recommended for
treatment (e.g., intravenous drug use, multiple sexual
partners)
At the start of incarceration, it is recommended that
trained personnel provide new inmates with
information on HCV infection, modes of
transmission, history, and disease management
At the start of incarceration, it is recommended that
trained personnel provide new inmates with
information on HBV infection, modes of
transmission, history, and disease management
HBV vaccination is recommended for any person
that falls into the high risk category (e.g., history of
STD, intravenous drug use, HBV or HIV infection,
tattooed in jail) or under the age of sixty with
diabetes
High risk inmates should be screened for HBV (e.g.,
intravenous drug use, pregnancy, history of STIs,
elevated ALT)
It should be determined whether HBV treatment is
necessary and the recommended approach
Before treating HCV, physicians must determine the
genotype of the virus which affects the most effective
course of antiviral treatment
Inmates that are confirmed to have acute HAV
should be isolated in order to avoid contagion; which
can last up to two weeks from the onset of symptoms
Any inmate that displays symptoms of hepatitis A
should be tested
Recommended to vaccinate certain individuals for
HAV including those with liver disease, cirrhosis,
clotting disorders, intravenous drug users, males who
engage in same-sex practices, and those at risk during
a HAV outbreak
Special consideration of antiviral treatment should be
given to people co-infected with HCV/HIV
Special consideration of antiviral treatment should be
given to people co-infected with HBV/HCV
An inmate with HAV should be monitored daily even
though there currently is not an effective treatment

73

Number of States
Requiring Criteria
18

Percentage of States
Requiring Criteria
36%

13

26%

13

26%

9

18%

8

16%

8

16%

7

14%

7

14%

7

14%

4

8%

2

4%

2

4%

1

2%

0

0%

0

0%

Table 8

Bivariate Analysis

Variables
Policy Comprehensiveness
States
% Foreign-born
% Nonwhite
Healthcare spending per capita
Median household income
Prison population
Hepatitis A rate in general pop.
Hepatitis B rate in general pop.
Hepatitis C rate in general pop.
% Inmate healthcare
Inmate healthcare spending
HIV infections in prison
HIV rate in prison

Policy Comprehensiveness
.154 (p = .284)
.101 (p = .486)
.076 (p = .598)
.054 (p = .709)
.027 (p = .852)
.237 (p = .283)
.230 (p = .190)
.031 (p = .835)
.154 (p = .336)
.145 (p = .387)
.036 (p = .844)
.331* (p = .045)
.309 (p = .179)

NOTE: *p<.10
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HCV Prison Prevalence
.146 (p = 441)
.132 (p = .487)
.014 (p = .940)
.240 (p= .202)
.045 (p= .814)
.205 (p= .277)
.094 (p= .598)
.059 (p = .756)
.175 (p = .355)
.045 (p = .828)
.249 (p = .192)
.163 (p = .457)
.223 (p = .244)
.218* (p = .079)

CHAPTER VII
DISCUSSION AND CONCLUSION

Few studies have examined hepatitis rates or hepatitis policies in prison. The
purpose of this research was thus two-fold: (1) to investigate how hepatitis policies in
state prisons affect hepatitis prevalence in these facilities while also exploring (2)
predictors of comprehensive policies and hepatitis prevalence from previous literature
and the Ecological Perspective. In this study, I aimed to test 10 hypotheses using original
data collected from each Department of Corrections. However, low response rates and
unforeseen setbacks in the data collection resulted in the use of secondary data for
analyses. Despite these setbacks, there were several important findings derived from this
study.
The framework for this study was shaped in part by the Ecological Perspective,
which examines six key components of health behavior: individual risk factors, social
relationships, living conditions, neighborhoods and communities, institutions, and social
and economic policies. In the context of individual risk factors, previous literature
suggested that certain people would be more likely to become infected. People who were
born outside of the United States, nonwhites, and males were more likely to become
infected with hepatitis (CDC, 2011). Social relationships within prison also affect
engagement in risky behaviors. Overcrowding and housing multiple inmates in one cell
may lead to problematic social exchanges, related to either unprotected sexual practices
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or intravenous drug use. People from disadvantaged communities in the general
population, who already have a higher probability of arrest, could also bring unhealthy
behaviors into the prison. Institutions, social and economic policies also play a critical
role in risk behaviors. These factors and their influence on hepatitis policies and
prevalence in prison will be discussed below.
Many of the 14 independent variables were drawn from the Ecological
Perspective. This theory posits that individual levels factors like race (measured by the
percent nonwhite), class (measured by the median household income), location
(measured by states), and healthcare expenditures (per capita) can affect risky behavior
(Kaplan, Everson, & Lynch, 2000). In the bivariate analysis, the percent of the population
that was non-white and the median household income were among the five strongest
correlates of HCV prevalence. Although these findings were not statistically significant,
there still may be some relationship between these factors and HCV prevalence.
Unfortunately, the data used for analysis did not allow for an exploration of individual
interactions. While changes in the institutional policies and the inmate population as a
whole are important to understand, research around individual interactions between
prisoners and how those interactions shape HCV prevalence is also needed. Future
research should thus explore how these individual person interactions affect HCV
prevalence within the prison population.
Of the 14 independent variables tested, the relationship between the number of
HIV infections in prison and comprehensive policies was statistically significant.
Therefore, the comprehensiveness of a state’s hepatitis policies is associated with HIV
prevalence in prison. States with more comprehensive policies had lower rates of HIV
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infection and improvements in policies would likely lower these rates even further.
Although not always statistically significant, analyses also revealed that HIV infections in
prison and the HIV prevalence rates in prison were the best correlates of HCV prevalence
in prison. These findings suggest that there is a close relationship between HIV and HCV.
Policies and practices that target HIV will likely have an effect on HCV because both
diseases are contracted through similar pathways. Positive movement towards decreases
in HIV rates should thus also decrease HCV rates. Conversely, changes in policies that
result in increases in HIV rates would probably increase HCV rates as well.
While it was theorized that healthcare spending would affect risky behaviors,
healthcare spending per capita appears to have no effect on prevalence rates. More likely,
targeted spending on certain areas is likely to affect HCV prevalence. The percent of the
DOC budget that is allocated for inmate healthcare is the second strongest correlate of
HCV prison prevalence. Consequently, it may be that the use of targeted spending in the
area of HCV is important to reducing the prevalence rate.
As prisons can be fairly transient, it was theorized that factors in the general
population would impact the prison population. However, what happens outside of prison
does not appear to have a significant impact on the occurrences in prison. This may be
due to the solitary nature of prisons and their removal from outside resources. Once
integrated in the prison system, inmates may be more affected by the day-to-day
operations within the facility because they have fewer opportunities to select who to
associate with and when. There could be many reasons why factors in the general
population do not significantly affect prison population, and this is an area that needs to
be further explored in future research.
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Location, according to the Ecological Perspective, can also affect risky behavior
(Kaplan, Everson, & Lynch, 2000). Risky behavior in prisons should be affected by
institutional policies; however, how comprehensive a policy is can either help or hinder
healthy behaviors. North Carolina, Pennsylvania, and Ohio had the most comprehensive
policies. These states met 7 of the 15 criteria from the BOP. However, a discernible
pattern among states (e.g., patterns by region, population, incarceration rates) did not
appear during analyses. Twenty states (40%) did not meet any of the BOP guidelines.
The 20 states with largely uncomprehensive policies were scattered throughout the
United States and were not located in one central region, as evidenced by the fact that
these states included Alaska, California, Louisiana, Maine, and Utah. Findings such as
this highlight that no one factor like population size or region can explain the
comprehensiveness of policies.
There was also wide variation between states in the use of BOP guidelines. While
states were most likely to have policies where they screened high risk inmates for HCV,
treated cases of HCV, and provided inmates with education on this disease, a number of
BOP guidelines were rarely mentioned in state policies. No states mentioned the need to
daily monitor inmates with HAV or provide extra consideration for people co-infected
with HBV and HCV. States more often included policies that would require sporadic or
one-time health visits, as opposed to daily health consultations. Of all the policies from
BOP, those addressing special treatment for people co-infected with multiple types of
hepatitis or HCV and HIV were rarely mentioned. This may be due to the fact that coinfection requires more frequent supervision and is costly. In addition, guidelines for
HAV were infrequently included in state policies. This could be due to the low incidence
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rate of HAV and the vaccination that is available. Nevertheless, failing to actively devote
time and resources to HAV could result in infections that may not have otherwise
occurred. States that have a large foreign-born population could have higher HAV rates
because of lower vaccination rates (WHO, 2013).
Considering the wide range of factors that affect a person’s likelihood of being
infected with a communicable disease, it is important to understand how both individual
choices and structural forces affect life choices. Additional research can apply these
theories to understanding how policies are created and under what circumstances.
Considering the high prevalence rate of HCV in the United States, it is imperative to
continue researching strategies to reduce its transmission. This research has
demonstrated that certain components of the ecological perspective are helpful in
explaining the comprehension of hepatitis policies in the United States. Nevertheless,
additional work in this area is sorely needed.
Limitations
Although the results of this study provide a number of important contributions
and directions for future research, there are also a number of limitations of this research.
First, there were several limitations of analyzing online policies. While the DOC offered
valuable information about current hepatitis policies, there may still be some variation
within state correctional facilities that was not reported online. Additionally, some of the
DOC websites were difficult to navigate and search terms were not always successful.
Several of the websites yielded no results and could not be analyzed in the preliminary
phase. Even with the policies that were available for each DOC, I was unable to ascertain
whether all of the policies were at my disposal, suggesting that some policies related to
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this topic might not be available to the public. In addition, some of the information
available online may be from previous versions and not the current policies in use. Many
of the policies were dated from the early to mid-2000s and few were dated recently,
suggesting the findings around these policies should be assessed with caution.
There were also limitations involved with the data available about HCV
prevalence. First, Carroll (2013) provided HCV prevalence data for only 38 states,
leaving HCV prevalence in prison unknown in 12 states. Additionally, nine states did not
report HCV prevalence in the 2012 Viral Hepatitis Surveillance Report. These missing
data limit the understanding of the prevalence of hepatitis in both the prison and general
population. Furthermore, even in those states where data were reported, the CDC (2012)
acknowledge that the known rates of hepatitis are only a fraction of the total number of
cases because of coverage error and sampling error occurring as part of their data
collection.
In addition to limitations experienced during the initial data collection, this study
was also unable to compare state and private prison policies. Private prisons may not
follow the Bureau of Prison guidelines and instead may operate on their own. Assessing
policies in all types of prisons is essential to understanding differences in prevalence rates
among the incarcerated population and whether those differences can be attributed to
population demographics or specific communicable disease policies and standards of
care.
Future Recommendations
Future research should continue to seek to understand factors that positively or
negatively affect the HCV prevalence rate in prison. Studies should also explore the
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circular relationship between hepatitis rates in the prison and those rates in the general
population. Gaining access to the 50 states’ DOCs is likely the most significant barrier
that researchers will need to overcome to continue to develop research in this area.
Finding individuals through groups like the American Correctional Association (ACA) or
the American Society of Criminology (ASC) that have contacts with their state’s DOC is
critical to gaining access to overcome these barriers. Enlisting these individual’s
assistance, and providing funding for their assistance if necessary, would be essential.
Each state likely has a particular person who works or has worked closed with the DOC
in that particular state. Therefore, enlisting the help of up to 50 individuals, if not more,
would be essential.
Additionally, future studies should pilot their questionnaire with at least one state
to ensure that the language in use is appropriate and understandable. In this particular
study, the inconsistency in the language used by the researcher and the DOC resulted in
some confusion. Despite replicating the questionnaire from Beck & Maruschak (2004),
the language of the survey differed from the current medical terminology. In particular,
the use of the word “testing” often confused participants that thought a more appropriate
word choice would be “screening.”
As with all survey research, it is important to consider the mode of distribution
(e.g., email, mail, and telephone), the time frame for data collection, and the allotted
budget. If at all possible, personally interviewing individuals with each state’s DOC
would be the optimal strategy. In that situation, because the researcher is present and
available, they can gather data quickly from other DOC partners that may be needed to
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gather the necessary information to understand the factors that predict hepatitis
prevalence and policy.
If that strategy is cost prohibitive, allowing states more than one way of
completing the survey may be advantageous, especially during certain times of the year.
However, the use of multiple modes of distribution would require the researcher to be
very diligent in their record keeping and to record any issues that arose to improve future
studies. Allowing states sufficient time to complete a questionnaire may allow for more
detailed responses, depending on the survey design. Periodic reminders about the study
may also increase response rates.
While much of the information about the inmate population is meant to be public
access, there may still be difficulty obtaining open records. Before initiating contact,
either with someone who works with DOC or works for DOC, it is important to review
each state’s policies on distributing data. Some states may prohibit the distribution of
records to some individuals (e.g., students), which may limit who can actually collect the
data. Other states require researchers to complete a research proposal stating the purpose
of the project and how the data will be used. States may require the final copy of the
report to be submitted to the agency at the conclusion of the study. The length of review
process varies by state, with some states reviewing projects within days, while others
may take months. The length of the review process will need to be taken into account
when constructing the data collection timeframe. All of these factors are essential to
consider before the onset of data collection.
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Conclusion
This study was an exploratory effort to understand the relationship between
hepatitis in the general population and hepatitis policy and rates in prison. It contributes
to the literature through the examination of individual, community, and institutional
factors and their effect on hepatitis rates in prison. Findings from explorations of current
correctional policies and rates of infectious disease (e.g., hepatitis, HIV) further
emphasize the need to continue research in this area. This study found a statistically
significant relationship between rates of HIV and HCV, suggesting policy aimed at one
of these diseases would likely impact the other. My hope is that this study provided a
foundation for future research and studies moving forward should seek to understand
policies that decrease rates of infectious disease. Even incremental progress in that
direction makes the time and energy put into this research worthwhile.
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APPENDIX A
COMMUNICABLE DISEASE SURVEY
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1. As of January 1, 2014, how many inmates were incarcerated in your state?
2. Does your state collect information about inmates’ place of birth?
Yes
No
3. As of January 1, 2014, how many inmates were…?
Natural Born Citizens?
Foreign Born?
4. Between January 1, 2013 and January 1, 2014, how many inmates died as a result
of…?
Natural Cause
Acquired Immune Deficiency Syndrome (AIDS)
Liver Disease
Suicide
Homicide
Other-Please Specify
5. Which of the following programs are available to inmates? Select all that apply.
Drug dependency/counseling
Alcohol dependency/counseling
Psychological/psychiatric counseling
HIV/AIDS counseling
Sex offender counseling
Other- Please specify
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6. As of January 1, 2014, how many staff members were employed in correctional
facilities…?
Administrators (Warden, superintendents…)
Correctional Officers (Non-administration)
Clerical and Maintenance Staff (Cooks, secretaries, groundskeepers…)
Educational Staff (Academics, vocational…)
Medical Staff (Doctors, Nurses, Dentists…)
Psychological Staff (Counselors, Psychologists, Psychiatrists…)
Other Staff (Not included in the above categories)
7. Between January 1, 2013 and January 1, 2014, how many reported disturbances
occurred?
Major Disturbances (incident involving 5+ inmates that caused serious physical
injury or property damage)
Other Disturbances (suicide, hunger strike…)
8. Between January 1, 2013 and January 1, 2014, were there any inmate inflicted physical
or sexual assaults on staff members? If yes, how many?
Yes
No
9. Do correctional facilities test for Human Immunodeficiency Virus (HIV)?
Yes
No
10. In what year did your facilities begin their first form of testing for Human
Immunodeficiency Virus (HIV)?
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11. Under what circumstances are inmates tested for the Human Immunodeficiency Virus
(HIV)? Select all that apply.
All inmates upon admission
All inmates upon release
Random sample of inmates
High risk group- Please specify
Upon inmate request
Upon clinical recommendations
Other- Please specify
12. As of January 1, 2014, how many inmates were…?
Asymptomatic HIV (no symptoms of HIV)
Symptomatic HIV (symptoms of HIV)
Other- Please specify
13. Is treatment available to inmates who have previously tested positive for Human
Immunodeficiency Virus (HIV)?
Yes
No
14. Do correctional facilities test for Tuberculosis (TB)?
Yes
No
15. In what year did your facilities begin their first form of testing for Tuberculosis (TB)?
16. Under what circumstances are inmates tested for Tuberculosis? Select all that apply.
All inmates upon admission
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All inmates upon release
Random sample of inmates
High risk group- Please specify
Upon inmate request
Upon clinical recommendations
Other- Please specify
17. As of January 1, 2014, how many inmates were...?
Positive for Tuberculosis-How many?
Negative for Tuberculosis-How many?
Other-How many?
18. Is treatment available to inmates who have previously tested positive for
Tuberculosis?
Yes
No
19. We are interested in information about hepatitis in prison in your state. Do
correctional facilities test for any form of hepatitis?
Yes
No
20. In what year did your facilities begin their first form of testing for hepatitis?
21. Do correctional facilities test for hepatitis A virus (HAV)?
Yes
No
22. In what year did your facilities begin their first form of testing for hepatitis A?
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23. Under what circumstances are inmates tested for hepatitis A? Select all that apply.
All inmates upon admission
All inmates upon release
Random sample of inmates
High risk group- Please specify
Upon inmate request
Upon clinical recommendation
Other- Please specify
24. Between January 1, 2013 and January 1, 2014, were any inmates tested for hepatitis
A?
Yes-How many?
No
25. Of the inmates tested for hepatitis A between January 1, 2013 and January 1, 2014,
were any confirmed positive or negative? How many? Select all that apply.
Confirmed positive- How many?
Confirmed negative- How many?
26. Is treatment available to inmates who have previously tested positive for hepatitis A?
Yes
No
27. Do correctional facilities offer vaccinations for hepatitis A?
Yes
No
28. Among inmates, who is eligible for hepatitis A vaccination? Select all that apply.
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All inmates
Inmates with a sexually transmitted disease
Inmates under the age of 18
High risk group- Please specify
Upon inmate request
Upon clinical recommendation
Other- Please specify
29. Between January 1, 2013 and January 1, 2014, how many inmates have completed the
vaccination series for hepatitis A?
30. Do correctional facilities test for hepatitis B virus (HBV)?
Yes
No
31. In what year did your facilities begin their first form of testing for hepatitis B?
32. Under what circumstances are inmates tested for hepatitis B? Select all that apply.
All inmates upon admission
All inmates upon release
Random sample of inmates
High risk group- Please specify
Upon inmate request
Upon clinical recommendation
Other- Please specify
33. Between January 1, 2013 and January 1, 2014, were any inmates tested for hepatitis
B?
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Yes-How many?
No
34. Of the inmates tested for hepatitis B between January 1, 2013 and January 1, 2014,
were any confirmed positive or negative? How many? Select all that apply.
Confirmed positive- How many?
Confirmed negative- How many?
35. Is treatment available to inmates who have previously tested positive for hepatitis B?
Yes
No
36. Do correctional facilities offer vaccinations for hepatitis B?
Yes
No
37. Among inmates, who is eligible for hepatitis B vaccination? Select all that apply.
All inmates
Inmates with a sexually transmitted disease
Inmates under the age of 18
High risk group- Please specify
Upon inmate request
Upon clinical recommendation
Other- Please specify
38. Between January 1, 2013 and January 1, 2014, how many inmates have completed the
vaccination series for hepatitis B?
39. Do correctional facilities test for hepatitis C?
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Yes
No
40. In what year did your facilities begin their first form of testing for hepatitis C?
41. Under what circumstances are inmates tested for hepatitis C? Select all that apply.
All inmates upon admission
All inmates upon release
Random sample of inmates
High risk group- Please specify
Upon inmate request
Upon clinical recommendation
Other- Please specify
42. Between January 1, 2013 and January 1, 2014, were any inmates tested for hepatitis
C?
Yes-How many?
No
43. Of the inmates tested for hepatitis C between January 1, 2013 and January 1, 2014,
were any confirmed positive or negative? How many? Select all that apply.
Confirmed positive- How many?
Confirmed negative- How many?
44. Is treatment available to inmates who have previously tested positive for hepatitis C?
Yes
No

98

45. Is there anything you would like to tell us about testing or treatment of communicable
diseases that we have not asked about?
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